CUMULATIVE SUPPLEMENT 04
April 2009



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

29th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2009

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

29th EDITION

Cumulative Supplement 4

April 2009

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

29th EDITION

CUMULATIVE SUPPLEMENT 4
April 2009

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 28th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 29th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 30th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@cder.fda.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
DABUR ONCOLOGY PLC (DABUR ONCOLOGY PLC)	FRESENIUS KABI ONCOLOGY PLC (FRESENIUS KABI ONCOL)
TORPHARM INC (TORPHARM)	APOTEX INC (APOTEX)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.fda.gov/cder/ob/default.htm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Annual Edition. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm . The drug product text files are provided in eobzip.exe and eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not

previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2008	MAR 2009	JUN 2009	SEPT 2009
DRUG PRODUCTS LISTED	12751	12910		
SINGLE SOURCE	2433	2449		
	(19.1%)	(19.0%)		
MULTISOURCE	10229	10372		
	(80.2%)	(80.3%)		
THERAPEUTICALLY EQUIVALENT	10072	10216		
	(79.0%)	(79.1%)		
NOT THERAPEUTICALLY EQUIVALENT	157	156		
	(1.2%)	(1.2%)		
EXCEPTIONS[1]	89	89		
	(0.7%)	(0.7%)		
NEW MOLECULAR ENTITIES APPROVED	15	5		
NUMBER OF APPLICANTS	719	724		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

		@ SANDOZ	300MG;30MG	N81250	001	Jul 16, 1992	Mar		DISC
		@	300MG;60MG	N81249	001	Jul 16, 1992	Mar		DISC

TYLENOL W/ CODEINE NO. 4

	AA	ORTHO MCNEIL JANSSEN	300MG;60MG	N85055	004		Mar		CMFD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

		@ MALLINCKRODT	500MG;5MG	N89006	001	Aug 09, 1985	Feb		CTNA

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

		@ SANDOZ	650MG;65MG	N89959	001	Jul 18, 1989	Mar		DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

		@ SANDOZ	650MG;100MG	N70443	001	Jan 23, 1986	Mar		DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>D>	AB	ALPHAPHARM	325MG;37.5MG	N77858	001	Sep 26, 2008	Apr		CAHN
>A>	AB	MYLAN	325MG;37.5MG	N77858	001	Sep 26, 2008	Apr		CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

>D>	AP	HOSPIRA	EQ 500MG BASE/VIAL	N40108	001	Oct 30, 1995	Apr		DISC
>A>		@	EQ 500MG BASE/VIAL	N40108	001	Oct 30, 1995	Apr		DISC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

>D>	AP	HOSPIRA	EQ 500MG BASE/VIAL	N74758	001	Apr 22, 1997	Apr		DISC
>A>		@	EQ 500MG BASE/VIAL	N74758	001	Apr 22, 1997	Apr		DISC
>D>	AP		EQ 1GM BASE/VIAL	N74758	002	Apr 22, 1997	Apr		DISC
>A>		@	EQ 1GM BASE/VIAL	N74758	002	Apr 22, 1997	Apr		DISC

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

>A>	AP	LUITPOLD	3MG/ML	N90010	001	Apr 28, 2009	Apr		NEWA

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

		@ ARMSTRONG PHARMS	0.09MG/INH	N72273	001	Aug 14, 1996	Jan		DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

>D>	AN	+	BAUSCH AND LOMB	EQ 0.083% BASE	N75358	001	Mar 29, 2000	Apr	DISC
>A>		@		EQ 0.083% BASE	N75358	001	Mar 29, 2000	Apr	DISC
	AN		HOLOPACK INTL	EQ 0.083% BASE	N77839	001	Dec 16, 2008	Jan	CAHN
>D>	AN		IVAX PHARMS	EQ 0.083% BASE	N75343	001	Nov 09, 1999	Apr	CAHN
>A>	AN		TEVA PARENTERAL	EQ 0.083% BASE	N75343	001	Nov 09, 1999	Apr	CAHN

TABLET; ORAL

ALBUTEROL SULFATE

		@	SANDOZ	EQ 2MG BASE	N72151	001	Dec 05, 1989	Mar	DISC
		@		EQ 4MG BASE	N72152	001	Dec 05, 1989	Mar	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

>D>	AN		IVAX PHARMS INC	EQ 0.083% BASE;0.017%	N76724	001	Dec 31, 2007	Apr	CAHN
>A>	AN		TEVA PARENTERAL	EQ 0.083% BASE;0.017%	N76724	001	Dec 31, 2007	Apr	CAHN

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

>A>	AB		SANDOZ	EQ 5MG BASE	N75871	001	Apr 22, 2009	Apr	NEWA
>A>	AB			EQ 10MG BASE	N75871	002	Apr 22, 2009	Apr	NEWA
>A>	AB			EQ 35MG BASE	N75871	004	Apr 22, 2009	Apr	NEWA
>A>	AB			EQ 40MG BASE	N75871	003	Apr 22, 2009	Apr	NEWA
>A>	AB			EQ 70MG BASE	N75871	005	Apr 22, 2009	Apr	NEWA

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

		@	SANDOZ	100MG	N70268	001	Dec 31, 1985	Mar	DISC
		@		300MG	N70269	001	Dec 31, 1985	Mar	DISC

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

	AB	+	PAR PHARM	5MG	N70346	001	Jan 22, 1986	Jan	CTEC
	AB		SIGMAPHARM LABS LLC	5MG	N79133	001	Jan 30, 2009	Jan	NEWA

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@	SANDOZ	EQ 5MG ANHYDROUS;50MG	N73357	001	Nov 27, 1991	Mar	DISC

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

>D>	AP		HOSPIRA	250MG/ML	N70888	001	Jun 16, 1988	Apr	DISC
>A>		@		250MG/ML	N70888	001	Jun 16, 1988	Apr	DISC

TABLET; ORAL

AMICAR

			XANODYNE PHARM	1GM	N15197	002	Jun 24, 2004	Jan	NEWA

AMINOPHYLLINE

INJECTABLE; INJECTION

>D>			AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%						
>D>		+	HOSPIRA	100MG/100ML	N88147	002	May 03, 1983	Apr	DISC
>A>		@		100MG/100ML	N88147	002	May 03, 1983	Apr	DISC
>D>		+		200MG/100ML	N88147	003	May 03, 1983	Apr	DISC
>A>		@		200MG/100ML	N88147	003	May 03, 1983	Apr	DISC

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

			AMIODARONE HYDROCHLORIDE						
>D>	AB		ALPHAPHARM	200MG	N75188	001	Feb 24, 1999	Apr	CAHN
>A>	AB		MYLAN	200MG	N75188	001	Feb 24, 1999	Apr	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

			AMLODIPINE BESYLATE						
>A>	AB		ALKEM	EQ 2.5MG BASE	N78925	001	May 04, 2009	Apr	NEWA
>A>	AB			EQ 5MG BASE	N78925	002	May 04, 2009	Apr	NEWA
>A>	AB			EQ 10MG BASE	N78925	003	May 04, 2009	Apr	NEWA
	AB		GLENMARK GENERICS	EQ 2.5MG BASE	N78552	001	Apr 08, 2009	Mar	NEWA
	AB			EQ 5MG BASE	N78552	002	Apr 08, 2009	Mar	NEWA
	AB			EQ 10MG BASE	N78552	003	Apr 08, 2009	Mar	NEWA
	AB		SYNTHON PHARMS	EQ 2.5MG BASE	N77080	001	Jun 27, 2007	Jan	CAHN
	AB			EQ 5MG BASE	N77080	002	Jun 27, 2007	Jan	CAHN
	AB			EQ 10MG BASE	N77080	003	Jun 27, 2007	Jan	CAHN

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

>A>			TABLET; ORAL						
>A>			EXFORGE HCT						
>A>			NOVARTIS	5MG;12.5MG;160MG	N22314	001	Apr 30, 2009	Apr	NEWA
>A>				5MG;25MG;160MG	N22314	002	Apr 30, 2009	Apr	NEWA
>A>				10MG;12.5MG;160MG	N22314	003	Apr 30, 2009	Apr	NEWA
>A>		+		10MG;25MG;320MG	N22314	005	Apr 30, 2009	Apr	NEWA
>A>				10MG;25MG;160MG	N22314	004	Apr 30, 2009	Apr	NEWA

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

			AMOXICILLIN AND CLAVULANATE POTASSIUM						
	AB		APOTEX	250MG;EQ 125MG BASE	N65333	001	Feb 24, 2009	Feb	NEWA
	AB			500MG;EQ 125MG BASE	N65333	002	Feb 24, 2009	Feb	NEWA

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

			APRACLONIDINE HYDROCHLORIDE						
	AT		AKORN INC	EQ 0.5% BASE	N77764	001	Mar 12, 2009	Feb	NEWA
			IOPIDINE						
	AT	+	ALCON	EQ 0.5% BASE	N20258	001	Jul 30, 1993	Feb	CFTG

ARMODAFINIL

TABLET; ORAL

			NUVIGIL						
			CEPHALON	100MG	N21875	002	Mar 26, 2009	Mar	CMFD
				200MG	N21875	005	Mar 26, 2009	Mar	NEWA

>A>	ARTEMETHER; LUMEFANTRINE								
>A>	TABLET; ORAL								
>A>	COARTEM								
>A>	NOVARTIS	20MG;120MG		N22268	001	Apr 07, 2009	Apr	NEWA	
	ASPIRIN; BUTALBITAL; CAFFEINE								
	TABLET; ORAL								
	BUTALBITAL, ASPIRIN AND CAFFEINE								
	@ SANDOZ	325MG;50MG;40MG		N86398	002	Apr 06, 1984	Mar	DISC	
	ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE								
	TABLET; ORAL								
	ORPHENGESIC								
	@ SOLCO HLTHCARE	385MG;30MG;25MG		N75141	001	May 29, 1998	Jan	CAHN	
	ORPHENGESIC FORTE								
	@ SOLCO HLTHCARE	770MG;60MG;50MG		N75141	002	May 29, 1998	Jan	CAHN	
	ATRACURIUM BESYLATE								
	INJECTABLE; INJECTION								
	ATRACURIUM BESYLATE								
	@ HOSPIRA	10MG/ML		N74740	001	Mar 28, 1997	Jan	DISC	
	ATRACURIUM BESYLATE PRESERVATIVE FREE								
	@ HOSPIRA	10MG/ML		N74741	001	Mar 28, 1997	Jan	DISC	
	AZACITIDINE								
	INJECTABLE; IV-SC								
	VIDAZA								
	+ CELGENE	100MG/VIAL		N50794	001	May 19, 2004	Mar	CAHN	
	AZELASTINE HYDROCHLORIDE								
	SPRAY, METERED; NASAL								
>D>	AZELASTINE HYDROCHLORIDE								
>A>	@ APOTEX INC	EQ 0.125MG BASE/SPRAY		N77954	001	Apr 30, 2009	Apr	DISC	
	AZITHROMYCIN								
	INJECTABLE; INJECTION								
	AZITHROMYCIN								
AP	SAGENT STRIDES	EQ 500MG BASE/VIAL		N65506	001	Mar 24, 2009	Mar	NEWA	
	BACLOFEN								
	TABLET; ORAL								
	BACLOFEN								
>D> AB	ALPHAPHARM	10MG		N77181	001	Jul 29, 2005	Apr	CAHN	
>D> AB		20MG		N77121	002	Jul 29, 2005	Apr	CAHN	
>A> AB	MYLAN	10MG		N77181	001	Jul 29, 2005	Apr	CAHN	
>A> AB		20MG		N77121	002	Jul 29, 2005	Apr	CAHN	
	BENZTROPINE MESYLATE								
	INJECTABLE; INJECTION								
	COGENTIN								
>A>	+ LUNDBECK INC	1MG/ML		N12015	001		Apr	CAHN	
>D>	+ OVATION PHARMS	1MG/ML		N12015	001		Apr	CAHN	

>A>		BENZYL ALCOHOL							
>A>		LOTION; TOPICAL							
>A>		BENZYL ALCOHOL							
>A>	+	SCIELE PHARMA INC	5%	N22129	001	Apr 09, 2009	Apr	NEWA	
		BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE							
		OINTMENT; TOPICAL							
		TACLONEX							
	+	LEO PHARM	0.064%;0.005%	N21852	001	Jan 09, 2006	Mar	CAHN	
		BETHANECHOL CHLORIDE							
		TABLET; ORAL							
		BETHANECHOL CHLORIDE							
>A>	AA	SUN PHARM INDS INC	5MG	N40897	001	Apr 22, 2009	Apr	NEWA	
>A>	AA		10MG	N40897	002	Apr 22, 2009	Apr	NEWA	
>A>	AA		25MG	N40897	003	Apr 22, 2009	Apr	NEWA	
>A>	AA		50MG	N40897	004	Apr 22, 2009	Apr	NEWA	
		BRIMONIDINE TARTRATE							
		SOLUTION/DROPS; OPHTHALMIC							
		BRIMONIDINE TARTRATE							
>D>	AT	IVAX PHARMS	0.2%	N76372	001	Sep 10, 2004	Apr	CAHN	
>A>	AT	TEVA PARENTERAL	0.2%	N76372	001	Sep 10, 2004	Apr	CAHN	
		BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE							
		SYRUP; ORAL							
		BROMFED-DM							
>D>	AA	BRIGHTON PHARMS INC	2MG/5ML;10MG/5ML;30MG/5ML	N89681	001	Dec 22, 1988	Apr	CAHN	
>A>	AA	WOCKHARDT EU	2MG/5ML;10MG/5ML;30MG/5ML	N89681	001	Dec 22, 1988	Apr	CAHN	
		BUDESONIDE							
		SUSPENSION; INHALATION							
		BUDESONIDE							
	AN	APOTEX	0.25MG/2ML	N78202	001	Mar 30, 2009	Mar	NEWA	
	AN		0.5MG/2ML	N78202	002	Mar 30, 2009	Mar	NEWA	
>D>	AN	IVAX PHARMS INC	0.25MG/2ML	N77519	001	Nov 18, 2008	Apr	CAHN	
>D>	AN		0.5MG/2ML	N77519	002	Nov 18, 2008	Apr	CAHN	
>A>	AN	TEVA PARENTERAL	0.25MG/2ML	N77519	001	Nov 18, 2008	Apr	CAHN	
>A>	AN		0.5MG/2ML	N77519	002	Nov 18, 2008	Apr	CAHN	
		BUPROPION HYDROCHLORIDE							
		TABLET, EXTENDED RELEASE; ORAL							
		BUPROPION HYDROCHLORIDE							
	AB1	WATSON LABS	100MG	N79095	001	Mar 24, 2009	Mar	NEWA	
	AB2		150MG	N79094	001	Mar 24, 2009	Mar	NEWA	
	AB1		150MG	N79095	002	Mar 24, 2009	Mar	NEWA	
	AB1		200MG	N79095	003	Mar 24, 2009	Mar	NEWA	
		BUSPIRONE HYDROCHLORIDE							
		TABLET; ORAL							
		BUSPAR							
	AB +	BRISTOL MYERS SQUIBB	15MG	N18731	003	Apr 22, 1996	Feb	CRLD	
	@		30MG	N18731	004	Apr 22, 1996	Feb	DISC	
		BUSPIRONE HYDROCHLORIDE							
	AB	DR REDDYS LABS LTD	5MG	N78246	001	Feb 27, 2009	Feb	NEWA	

		TABLET; ORAL							
		BUSPIRONE HYDROCHLORIDE							
	AB	DR REDDYS LABS LTD	10MG	N78246	002	Feb 27, 2009	Feb	NEWA
	AB		15MG	N78246	003	Feb 27, 2009	Feb	NEWA
	AB		30MG	N78246	004	Feb 27, 2009	Feb	NEWA
>A>	AB	MYLAN	5MG	N75467	001	Feb 28, 2002	Apr	CAHN
>A>	AB		7.5MG	N75467	002	Mar 28, 2001	Apr	CAHN
>A>	AB		10MG	N75467	003	Feb 28, 2002	Apr	CAHN
>A>	AB		15MG	N75467	004	Feb 28, 2002	Apr	CAHN
>D>	AB	PAR PHARM	5MG	N75467	001	Feb 28, 2002	Apr	CAHN
>D>	AB		7.5MG	N75467	002	Mar 28, 2001	Apr	CAHN
>D>	AB		10MG	N75467	003	Feb 28, 2002	Apr	CAHN
>D>	AB		15MG	N75467	004	Feb 28, 2002	Apr	CAHN
		@ SANDOZ	5MG	N75413	001	Mar 19, 2002	Mar	DISC
		@	10MG	N75413	002	Mar 19, 2002	Mar	DISC
		@	15MG	N75413	003	Mar 19, 2002	Mar	DISC
		BUTORPHANOL TARTRATE							
		INJECTABLE; INJECTION							
		BUTORPHANOL TARTRATE							
>A>	AP	HIKMA FARMACEUTICA	1MG/ML	N78400	001	May 01, 2009	Apr	NEWA
>A>	AP		2MG/ML	N78247	001	Apr 29, 2009	Apr	NEWA
>A>	AP		2MG/ML	N78400	002	May 01, 2009	Apr	NEWA
		CAFFEINE CITRATE							
		SOLUTION; INTRAVENOUS							
		CAFFEINE CITRATE							
>A>	AP	PADDOCK LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N77233	001	Sep 21, 2006	Apr	CAHN
>D>	AP	PHARMAFORCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N77233	001	Sep 21, 2006	Apr	CAHN
		CALCITRIOL							
		CAPSULE; ORAL							
		ROCALTROL							
	AB	VALIDUS PHARMS	0.25UGM	N18044	001		Mar	CAHN
	AB	+	0.5UGM	N18044	002		Mar	CAHN
		OINTMENT; TOPICAL							
		VECTICAL							
		+ GALDERMA LABS LP	3UGM/GM	N22087	001	Jan 23, 2009	Jan	NEWA
		SOLUTION; ORAL							
		ROCALTROL							
	AA	+ VALIDUS PHARMS	1UGM/ML	N21068	001	Nov 20, 1998	Mar	CAHN
		CARBAMAZEPINE							
		TABLET; ORAL							
		CARBAMAZEPINE							
>D>		CARACO	100MG	N77272	001	Dec 07, 2005	Apr	CAHN
>D>	AB		200MG	N77272	002	Dec 07, 2005	Apr	CAHN
>D>			300MG	N77272	003	Dec 07, 2005	Apr	CAHN
>D>			400MG	N77272	004	Dec 07, 2005	Apr	CAHN
>A>		TORRENT PHARMS	100MG	N77272	001	Dec 07, 2005	Apr	CAHN
>A>	AB		200MG	N77272	002	Dec 07, 2005	Apr	CAHN
>A>			300MG	N77272	003	Dec 07, 2005	Apr	CAHN
>A>			400MG	N77272	004	Dec 07, 2005	Apr	CAHN

TABLET, CHEWABLE; ORAL
CARBAMAZEPINE

AB		TORRENT PHARMS	100MG	N75712	001	Jul 05, 2001	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL
CARBAMAZEPINE

AB		TARO	100MG	N78115	001	Mar 31, 2009	Mar	NEWA
AB			200MG	N78115	002	Mar 31, 2009	Mar	NEWA
AB			400MG	N78115	003	Mar 31, 2009	Mar	NEWA

TEGRETOL-XR

AB		NOVARTIS	100MG	N20234	001	Mar 25, 1996	Mar	CFTG
AB			200MG	N20234	002	Mar 25, 1996	Mar	CFTG
AB	+		400MG	N20234	003	Mar 25, 1996	Mar	CFTG

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL
GEOCILLIN

		@ PFIZER	EQ 382MG BASE	N50435	001		Mar	DISC

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

		@ SANDOZ	10MG;100MG	N73586	001	Jun 29, 1995	Mar	DISC
		@	25MG;100MG	N73587	001	Jun 29, 1995	Mar	DISC
		@	25MG;250MG	N73620	001	Jun 29, 1995	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL
CARBIDOPA AND LEVODOPA

>D>	BX	KV PHARM	50MG;200MG	N76663	001	Jun 24, 2004	Apr	DISC
>A>		@	50MG;200MG	N76663	001	Jun 24, 2004	Apr	DISC

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN

>D>	AP	+	PHARMACHEMIE	50MG/VIAL	N76162	001	Oct 14, 2004	Apr	CAHN
>D>	AP	+		150MG/VIAL	N76162	002	Oct 14, 2004	Apr	CAHN
>D>	AP	+		450MG/VIAL	N76162	003	Oct 14, 2004	Apr	CAHN
>A>	AP	+	WATSON LABS	50MG/VIAL	N76162	001	Oct 14, 2004	Apr	CAHN
>A>	AP	+		150MG/VIAL	N76162	002	Oct 14, 2004	Apr	CAHN
>A>	AP	+		450MG/VIAL	N76162	003	Oct 14, 2004	Apr	CAHN

INJECTABLE; IV (INFUSION)
CARBOPLATIN

AP		PHARMACHEMIE BV	EQ 50MG/5ML (10MG/ML)	N77679	001	Feb 25, 2009	Feb	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N77679	003	Feb 25, 2009	Feb	NEWA
AP			EQ 150MG/15ML (10MG/ML)	N77679	002	Feb 25, 2009	Feb	NEWA

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

		@ SANDOZ	350MG	N81025	001	Apr 13, 1989	Mar	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP		CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	N65280	001	Mar 18, 2009	Mar	NEWA
AP			EQ 1GM BASE/VIAL	N65280	002	Mar 18, 2009	Mar	NEWA
AP			EQ 10GM BASE/VIAL	N65295	001	Mar 18, 2009	Mar	NEWA
AP			EQ 20GM BASE/VIAL	N65296	001	Mar 18, 2009	Mar	NEWA

INJECTABLE; INJECTION
CEFAZOLIN SODIUM
@ GLAXOSMITHKLINE EQ 1GM BASE/VIAL N64033 001 Oct 31, 1993 Mar DISC

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE
AP + SANDOZ EQ 2GM BASE/VIAL N65169 004 May 09, 2005 Mar CRLD

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL
CETIRIZINE HYDROCHLORIDE
>A> AA DR REDDYS LABS LTD 5MG/5ML N78870 001 Apr 27, 2009 Apr NEWA

CHLOROTHIAZIDE

TABLET; ORAL
DIURIL
>A> @ LUNDBECK INC 250MG N11145 004 Apr CAHN
>A> @ 500MG N11145 002 Apr CAHN
>D> @ OVATION PHARMS 250MG N11145 004 Apr CAHN
>D> @ 500MG N11145 002 Apr CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
DIURIL
>A> + LUNDBECK INC EQ 500MG BASE/VIAL N11145 005 Apr CAHN
>D> + OVATION PHARMS EQ 500MG BASE/VIAL N11145 005 Apr CAHN

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE
@ SANDOZ 100MG N88725 001 Aug 31, 1984 Mar DISC
@ 250MG N88726 001 Aug 31, 1984 Mar DISC

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE
@ SANDOZ 250MG N89852 001 May 04, 1988 Mar DISC
@ 500MG N89853 001 May 04, 1988 Mar DISC
>D> AA TEVA 500MG N89859 001 May 04, 1988 Apr CAHN
>A> AA WATSON LABS 500MG N89859 001 May 04, 1988 Apr CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL
TRILIPIX
ABBOTT LABS EQ 45MG FENOFIBRIC ACID N22224 001 Dec 15, 2008 Jan CTNA
+ EQ 135MG FENOFIBRIC ACID N22224 002 Dec 15, 2008 Jan CTNA

CHYMOPAPAIN

INJECTABLE; INJECTION
CHYMODIACTIN
@ CHART MEDCL 4,000 UNITS/VIAL N18663 002 Aug 21, 1984 Mar CAHN
@ 10,000 UNITS/VIAL N18663 001 Nov 10, 1982 Mar CAHN

CIMETIDINE

TABLET; ORAL
CIMETIDINE

	@ SANDOZ	200MG	N74100	001	Jan 31, 1995	Mar	DISC
	@	300MG	N74100	002	Jan 31, 1995	Mar	DISC
	@	400MG	N74100	003	Jan 31, 1995	Mar	DISC
	@	800MG	N74100	004	Jan 31, 1995	Mar	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL
CIPROFLOXACIN HYDROCHLORIDE

AB	MYLAN	EQ 250MG BASE	N75685	002	Jun 09, 2004	Mar	CMFD
AB		EQ 500MG BASE	N75685	003	Jun 09, 2004	Mar	CMFD
AB		EQ 750MG BASE	N75685	001	Jun 09, 2004	Mar	CMFD
	@ TEVA	EQ 250MG BASE	N76136	001	Jun 09, 2004	Jan	DISC
	@	EQ 500MG BASE	N76136	002	Jun 09, 2004	Jan	DISC
	@	EQ 750MG BASE	N76136	003	Jun 09, 2004	Jan	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

AB	AMNEAL PHARMS	EQ 10MG BASE	N77045	003	Apr 29, 2005	Feb	CAHN
AB		EQ 20MG BASE	N77045	002	Apr 29, 2005	Feb	CAHN
AB		EQ 40MG BASE	N77045	001	Apr 29, 2005	Feb	CAHN
AB	GLENMARK GENERICS	EQ 10MG BASE	N77654	001	Feb 27, 2009	Feb	NEWA
AB		EQ 20MG BASE	N77654	002	Feb 27, 2009	Feb	NEWA
AB		EQ 40MG BASE	N77654	003	Feb 27, 2009	Feb	NEWA

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HYDROCHLORIDE

	@ SANDOZ	0.1MG	N70887	001	Aug 31, 1988	Mar	DISC
	@	0.2MG	N70886	001	Aug 31, 1988	Mar	DISC
	@	0.3MG	N71294	001	Aug 31, 1988	Mar	DISC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

	@ SANDOZ	3.75MG	N72219	001	Aug 26, 1988	Mar	DISC

TRANXENE

>A>	@ LUNDBECK INC	3.75MG	N17105	001		Apr	CAHN
>A>	@	7.5MG	N17105	002		Apr	CAHN
>A>	@	15MG	N17105	003		Apr	CAHN
>D>	@ OVATION PHARMS	3.75MG	N17105	001		Apr	CAHN
>D>	@	7.5MG	N17105	002		Apr	CAHN
>D>	@	15MG	N17105	003		Apr	CAHN

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

	@ SANDOZ	7.5MG	N72513	001	May 11, 1990	Mar	DISC
	@	15MG	N72514	001	May 11, 1990	Mar	DISC

TRANXENE

>A>	AB	LUNDBECK INC	3.75MG	N17105	006		Apr	CAHN
>A>	AB		7.5MG	N17105	007		Apr	CAHN
>A>	AB	+	15MG	N17105	008		Apr	CAHN
>D>	AB	OVATION PHARMS	3.75MG	N17105	006		Apr	CAHN

		TABLET; ORAL								
		TRANXENE								
>D>	AB	OVATION PHARMS	7.5MG	N17105	007			Apr	CAHN
>D>	AB	+	15MG	N17105	008			Apr	CAHN
		TRANXENE SD								
>A>		LUNDBECK INC	11.25MG	N17105	005			Apr	CAHN
>A>		+	22.5MG	N17105	004			Apr	CAHN
>D>		OVATION PHARMS	11.25MG	N17105	005			Apr	CAHN
>D>		+	22.5MG	N17105	004			Apr	CAHN
		CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE								
		SYRUP; ORAL								
		TRIACIN-C								
>D>		+ STAT-TRADE	10MG/5ML;30MG/5ML;1.25MG/5ML	N88704	001	Mar 22, 1985		Apr	CAHN
>A>		+ STI PHARMA LLC	10MG/5ML;30MG/5ML;1.25MG/5ML	N88704	001	Mar 22, 1985		Apr	CAHN
		COLISTIMETHATE SODIUM								
		INJECTABLE; INJECTION								
>D>		COLISTIMETHATE								
>D>	AP	PADDOCK	EQ 150MG BASE/VIAL	N65177	001	Mar 19, 2004		Apr	CTNA
>D>	AP	X GEN PHARMS	EQ 150MG BASE/VIAL	N64216	001	Feb 26, 1999		Apr	CTNA
>A>		COLISTIMETHATE SODIUM								
>A>	AP	PADDOCK	EQ 150MG BASE/VIAL	N65177	001	Mar 19, 2004		Apr	CTNA
>A>	AP	X GEN PHARMS	EQ 150MG BASE/VIAL	N64216	001	Feb 26, 1999		Apr	CTNA
		CROMOLYN SODIUM								
		SOLUTION; INHALATION								
		CROMOLYN SODIUM								
>D>	AN	+ IVAX PHARMS	10MG/ML	N75271	001	Jan 18, 2000		Apr	CAHN
>A>	AN	+ TEVA PARENTERAL	10MG/ML	N75271	001	Jan 18, 2000		Apr	CAHN
		CYANOCOBALAMIN								
		GEL, METERED; NASAL								
		NASCOBAL								
		@ PAR PHARM	0.5MG/INH	N19722	001	Nov 05, 1996		Mar	CAHN
		CYCLOPHOSPHAMIDE								
		INJECTABLE; INJECTION								
		CYTOXAN								
		@ BAXTER HLTHCARE	100MG/VIAL	N12142	001			Feb	CAHN
		@	200MG/VIAL	N12142	002			Feb	CAHN
		@	500MG/VIAL	N12142	003			Feb	CAHN
		@	1GM/VIAL	N12142	004	Aug 30, 1982		Feb	CAHN
		@	2GM/VIAL	N12142	005	Aug 30, 1982		Feb	CAHN
		LYOPHILIZED CYTOXAN								
		+ BAXTER HLTHCARE	100MG/VIAL	N12142	006	Dec 05, 1985		Feb	CAHN
		+	200MG/VIAL	N12142	007	Dec 10, 1985		Feb	CAHN
	AP	+	500MG/VIAL	N12142	008	Jan 04, 1984		Feb	CAHN
	AP	+	1GM/VIAL	N12142	010	Sep 24, 1985		Feb	CAHN
	AP	+	2GM/VIAL	N12142	009	Dec 10, 1984		Feb	CAHN
		TABLET; ORAL								
		CYTOXAN								
		@ BAXTER HLTHCARE	25MG	N12141	002			Feb	CAHN
		@	50MG	N12141	001			Feb	CAHN

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

>A>		+	LUNDBECK INC	0.5MG/VIAL	N50682	001		Apr	CAHN
>D>		+	OVATION PHARMS	0.5MG/VIAL	N50682	001		Apr	CAHN

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

>D>	AP		TEVA PARENTERAL	500MG/VIAL	N76806	001	Mar 31, 2006	Apr	CAHN
>D>	AP			2GM/VIAL	N76806	002	Mar 31, 2006	Apr	CAHN
>A>	AP		WATSON LABS	500MG/VIAL	N76806	001	Mar 31, 2006	Apr	CAHN
>A>	AP			2GM/VIAL	N76806	002	Mar 31, 2006	Apr	CAHN

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21

DESOGESTREL AND ETHINYL ESTRADIOL

		@	DURAMED PHARMS BARR	0.15MG;0.03MG	N75256	001	Aug 12, 1999	Feb	DISC

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

>D>	AA	+	STAT-TRADE	0.5MG/5ML	N84754	001		Apr	CAHN
>A>	AA	+	STI PHARMA LLC	0.5MG/5ML	N84754	001		Apr	CAHN

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS; OPHTHALMIC

TOBRADEX ST

		+	ALCON	0.05%;0.3%	N50818	001	Feb 13, 2009	Feb	NEWA

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

KAPIDEX

			TAKEDA PHARMS	30MG	N22287	001	Jan 30, 2009	Jan	NEWA
		+		60MG	N22287	002	Jan 30, 2009	Jan	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

	AA	+	BARR	10MG	N40361	002	Jan 31, 2001	Mar	CRLD

DEXTROSTAT

		@	SHIRE	5MG	N84051	001		Mar	DISC
		@		10MG	N84051	002		Mar	DISC

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 60% IN PLASTIC CONTAINER

>D>	AP	+	HOSPIRA	60GM/100ML	N19346	001	Jan 25, 1985	Apr	DISC
>A>		@		60GM/100ML	N19346	001	Jan 25, 1985	Apr	DISC

DIAZEPAM

TABLET; ORAL

DIAZEPAM

		@	SANDOZ	2MG	N70302	001	Dec 20, 1985	Mar	DISC
		@		5MG	N70303	001	Dec 20, 1985	Mar	DISC

TABLET; ORAL
DIAZEPAM
@ SANDOZ 10MG N70304 001 Dec 20, 1985 Mar DISC

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL
DIETHYLPROPION HYDROCHLORIDE
AA COREPHARMA 25MG N40828 001 Nov 05, 2008 Feb CTEC
TENUATE
AA + WATSON PHARMS 25MG N11722 002 Feb CTEC

DIFLUNISAL

TABLET; ORAL
DIFLUNISAL
@ SANDOZ 500MG N74604 001 Jun 10, 1996 Mar DISC
+ TEVA 500MG N73673 001 Jul 31, 1992 Mar CTEC

DIGOXIN

INJECTABLE; INJECTION
DIGOXIN
>D> AP HOSPIRA 0.25MG/ML N40206 001 Aug 28, 1998 Apr DISC
>A> @ 0.25MG/ML N40206 001 Aug 28, 1998 Apr DISC

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILT-CD
>A> AB3 APOTEX 300MG N76151 004 May 20, 2004 Apr CAHN
>D> AB3 TORPHARM 300MG N76151 004 May 20, 2004 Apr CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HYDROCHLORIDE
+ BARR 50MG N80738 001 Mar CRLD
@ LNK 25MG N87977 001 Jan 27, 1983 Mar DISC
@ 50MG N87978 001 Jan 27, 1983 Mar DISC
@ SANDOZ 25MG N80832 001 Mar DISC
@ 50MG N80832 002 Mar DISC
@ VALEANT PHARM INTL 50MG N80592 001 Mar DISC
@ WATSON LABS 25MG N80728 001 Mar DISC
@ 50MG N80727 001 Mar DISC

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE
@ SANDOZ 25MG N86944 002 Apr 16, 1991 Mar DISC
@ 50MG N87562 001 Feb 25, 1992 Mar DISC
@ 75MG N87561 001 Feb 25, 1992 Mar DISC

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DEPAKOTE
AB + ABBOTT EQ 125MG VALPROIC ACID N19680 001 Sep 12, 1989 Jan CFTG
DIVALPROEX SODIUM
AB DR REDDYS LABS LTD EQ 125MG VALPROIC ACID N78979 001 Jan 23, 2009 Jan NEWA
AB ZYDUS PHARMS USA INC EQ 125MG VALPROIC ACID N78919 001 Jan 27, 2009 Jan NEWA

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

AB	MYLAN	EQ 125MG VALPROIC ACID	N90062	001	Mar 17, 2009	Mar	NEWA
AB		EQ 250MG VALPROIC ACID	N90062	002	Mar 17, 2009	Mar	NEWA
AB		EQ 500MG VALPROIC ACID	N90062	003	Mar 17, 2009	Mar	NEWA
AB	ZYDUS PHARMS USA INC	EQ 125MG VALPROIC ACID	N77100	001	Mar 05, 2009	Feb	NEWA
AB		EQ 250MG VALPROIC ACID	N77100	002	Mar 05, 2009	Feb	NEWA
AB		EQ 500MG VALPROIC ACID	N77100	003	Mar 05, 2009	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL
DEPAKOTE ER

AB	ABBOTT	EQ 250MG VALPROIC ACID	N21168	002	May 31, 2002	Jan	CFTG
AB +		EQ 500MG VALPROIC ACID	N21168	001	Aug 04, 2000	Jan	CFTG

DIVALPROEX SODIUM

AB	ANCHEN PHARMS	EQ 250MG VALPROIC ACID	N78445	001	Feb 26, 2009	Feb	NEWA
>A> AB	IMPAX LABS	EQ 250MG VALPROIC ACID	N78791	001	May 06, 2009	Apr	NEWA
AB	MYLAN	EQ 250MG VALPROIC ACID	N77567	001	Jan 29, 2009	Jan	NEWA
AB		EQ 500MG VALPROIC ACID	N77567	002	Jan 29, 2009	Jan	NEWA
AB	WOCKHARDT	EQ 250MG VALPROIC ACID	N78705	002	Feb 10, 2009	Jan	NEWA
AB	ZYDUS PHARMS USA INC	EQ 250MG VALPROIC ACID	N78239	001	Feb 27, 2009	Feb	NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

AT	ALCON	EQ 2% BASE	N78981	001	Apr 13, 2009	Mar	NEWA

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

+	PAR PHARM	EQ 150MG BASE	N65055	003	Jul 15, 2005	Jan	CRLD

TABLET; ORAL
DOXYCYCLINE

AB	MUTUAL PHARM	EQ 50MG BASE	N65471	001	Apr 17, 2009	Mar	NEWA
AB		EQ 75MG BASE	N65471	002	Apr 17, 2009	Mar	NEWA
AB		EQ 100MG BASE	N65471	003	Apr 17, 2009	Mar	NEWA

DRONABINOL

CAPSULE; ORAL
DRONABINOL

AB	SVC PHARMA	2.5MG	N78292	001	Jun 27, 2008	Mar	CAHN
AB		5MG	N78292	002	Jun 27, 2008	Mar	CAHN
AB		10MG	N78292	003	Jun 27, 2008	Mar	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL
DROSPIRENONE AND ETHINYL ESTRADIOL

AB	BARR	3MG;0.02MG	N78515	001	Mar 30, 2009	Mar	NEWA

YAZ

AB +	BAYER HLTHCARE	3MG;0.02MG	N21676	001	Mar 16, 2006	Mar	CFTG

ENALAPRIL MALEATE

TABLET; ORAL
ENALAPRIL MALEATE

@	SANDOZ	2.5MG	N75048	001	Aug 22, 2000	Mar	DISC
@		5MG	N75048	002	Aug 22, 2000	Mar	DISC
@		10MG	N75048	003	Aug 22, 2000	Mar	DISC
@		20MG	N75048	004	Aug 22, 2000	Mar	DISC

ENALAPRILAT

INJECTABLE; INJECTION

		ENALAPRILAT						
AP	+	HOSPIRA	1.25MG/ML	N75458	001	Aug 22, 2000	Feb	CRLD
		VASOTEC						
		@ BIOVAIL LABS INTL	1.25MG/ML	N19309	001	Feb 09, 1988	Feb	DISC

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

>D>		CITANEST FORTE						
>D>	+	DENTSPLY PHARM	0.005MG/ML;4%	N21383	001		Apr	CTNA
>A>		CITANEST FORTE DENTAL						
>A>	+	DENTSPLY PHARM	0.005MG/ML;4%	N21383	001		Apr	CTNA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

>A>		XYLOCAINE DENTAL WITH EPINEPHRINE						
>A> AP	+	DENTSPLY PHARM	0.01MG/ML;2%	N21381	001		Apr	CTNA
>A> AP	+		0.02MG/ML;2%	N21381	002		Apr	CTNA
		XYLOCAINE W/ EPINEPHRINE						
>D>		@ APP PHARMS	0.02MG/ML;2%	N06488	005		Apr	CMFD
>A> AP	+		0.02MG/ML;2%	N06488	005		Apr	CMFD
>D> AP	+	DENTSPLY PHARM	0.01MG/ML;2%	N21381	001		Apr	CTNA
>D> AP	+		0.02MG/ML;2%	N21381	002		Apr	CTNA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

		EPOPROSTENOL SODIUM						
>A>	+	ACTELION	EQ 1.5MG BASE/VIAL	N22260	001	Jun 27, 2008	Apr	CAHN
>D>	+	GENERAMEDIX	EQ 1.5MG BASE/VIAL	N22260	001	Jun 27, 2008	Apr	CAHN

>D> ERYTHROMYCIN ESTOLATE

>D> SUSPENSION; ORAL

>D>		ERYTHROMYCIN ESTOLATE						
>D>		ALPHARMA US PHARMS	EQ 125MG BASE/5ML	N62353	001	Nov 18, 1982	Apr	DISC
>A>		@	EQ 125MG BASE/5ML	N62353	001	Nov 18, 1982	Apr	DISC
>D>	+		EQ 250MG BASE/5ML	N62409	001	Dec 16, 1982	Apr	DISC
>A>		@	EQ 250MG BASE/5ML	N62409	001	Dec 16, 1982	Apr	DISC

ERYTHROMYCIN ETHYLSUCCINATE

SUSPENSION; ORAL

>D>		ERYTHROMYCIN ETHYLSUCCINATE						
>D> AB		ALPHARMA US PHARMS	EQ 200MG BASE/5ML	N62200	001		Apr	DISC
>A>		@	EQ 200MG BASE/5ML	N62200	001		Apr	DISC
>D> AB			EQ 400MG BASE/5ML	N62200	002		Apr	DISC
>A>		@	EQ 400MG BASE/5ML	N62200	002		Apr	DISC

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

		ERYZOLE						
		@ ALRA	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N62758	001	Jun 15, 1988	Jan	DISC
		PEDIAZOLE						
		@ ROSS LABS	EQ 200MG BASE/5ML;EQ 600MG BASE/5ML	N50529	001		Jan	DISC

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

	@ HOSPIRA	EQ 1GM BASE/VIAL	N50182	003		Feb	DISC
AP	+	EQ 1GM BASE/VIAL	N62638	002	Oct 31, 1986	Feb	CRLD

ESTRADIOL

TABLET; ORAL

INNOFEM

>D>	AB	NOVO NORDISK INC	0.5MG	N40312	001	Nov 19, 1999	Apr	DISC
>A>		@	0.5MG	N40312	001	Nov 19, 1999	Apr	DISC
>D>	AB		1MG	N40312	002	Nov 19, 1999	Apr	DISC
>A>		@	1MG	N40312	002	Nov 19, 1999	Apr	DISC
>D>	AB		2MG	N40312	003	Nov 19, 1999	Apr	DISC
>A>		@	2MG	N40312	003	Nov 19, 1999	Apr	DISC

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

MYAMBUTOL

	AB	STI PHARMA LLC	100MG	N16320	001		Mar	CAHN
		@	200MG	N16320	002		Mar	CAHN
	AB		400MG	N16320	003		Mar	CAHN
		@	500MG	N16320	004		Mar	CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-21

DEMULEN 1/35-21

>D>	AB	+ GD SEARLE LLC	0.035MG;1MG	N18168	001		Apr	DISC
>A>		@	0.035MG;1MG	N18168	001		Apr	DISC

DEMULEN 1/50-21

>D>	AB	+ GD SEARLE LLC	0.05MG;1MG	N16927	001		Apr	DISC
>A>		@	0.05MG;1MG	N16927	001		Apr	DISC

ZOVIA 1/35E-21

>D>	AB	WATSON LABS	0.035MG;1MG	N72720	001	Dec 30, 1991	Apr	DISC
>A>		@	0.035MG;1MG	N72720	001	Dec 30, 1991	Apr	DISC

ZOVIA 1/50E-21

>D>	AB	WATSON LABS	0.05MG;1MG	N72722	001	Dec 30, 1991	Apr	DISC
>A>		@	0.05MG;1MG	N72722	001	Dec 30, 1991	Apr	DISC

TABLET; ORAL-28

DEMULEN 1/35-28

>D>	AB	+ GD SEARLE LLC	0.035MG;1MG	N18160	001		Apr	DISC
>A>		@	0.035MG;1MG	N18160	001		Apr	DISC

DEMULEN 1/50-28

>D>	AB	GD SEARLE LLC	0.05MG;1MG	N16936	001		Apr	DISC
>A>		@	0.05MG;1MG	N16936	001		Apr	DISC

ZOVIA 1/50E-28

>D>	AB	WATSON LABS	0.05MG;1MG	N72723	001	Dec 30, 1991	Apr	CRLD
>A>		+	0.05MG;1MG	N72723	001	Dec 30, 1991	Apr	CRLD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

TRIPHASIL-21

>A>		@ AKRIMAX PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19192	001	Nov 01, 1984	Apr	CAHN

		TABLET; ORAL-21								
		TRIPHASIL-21								
>D>		@ WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19192	001	Nov 01, 1984	Apr	CAHN		
		TABLET; ORAL-28								
		TRIPHASIL-28								
>D>	AB	WYETH PHARMS INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19190	001	Nov 01, 1984	Apr	DISC		
>A>		@	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	N19190	001	Nov 01, 1984	Apr	DISC		
		ETHINYL ESTRADIOL; NORETHINDRONE								
		TABLET; ORAL-21								
		NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)								
>D>		+ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71041	001	Sep 24, 1991	Apr	CRLD		
>A>			0.035MG,0.035MG;0.5MG,1MG	N71041	001	Sep 24, 1991	Apr	CRLD		
		TABLET; ORAL-28								
		NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)								
>D>	AB	WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	N71044	001	Apr 01, 1988	Apr	CTEC		
>A>			0.035MG,0.035MG;0.5MG,1MG	N71044	001	Apr 01, 1988	Apr	CTEC		
		ORTHO-NOVUM 10/11-28								
		@ ORTHO MCNEIL JANSSEN	0.035MG,0.035MG;0.5MG,1MG	N18354	002	Jan 11, 1982	Mar	DISC		
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE								
		TABLET; ORAL-21								
		LOESTRIN 21 1.5/30								
>D>	AB	+ WARNER CHILCOTT	0.03MG;1.5MG	N17875	001		Apr	CRLD		
>A>	AB		0.03MG;1.5MG	N17875	001		Apr	CRLD		
		LOESTRIN 21 1/20								
>D>	AB	+ WARNER CHILCOTT	0.02MG;1MG	N17876	001		Apr	CRLD		
>A>	AB		0.02MG;1MG	N17876	001		Apr	CRLD		
		TABLET; ORAL-28								
		LOESTRIN FE 1/20								
>D>	AB	+ WARNER CHILCOTT	0.02MG;1MG	N17354	001		Apr	CRLD		
>A>	AB		0.02MG;1MG	N17354	001		Apr	CRLD		
		ETHINYL ESTRADIOL; NORGESTREL								
		TABLET; ORAL-21								
>D>		OGESTREL 0.5/50-21								
>D>		+ WATSON LABS	0.05MG;0.5MG	N75406	001	Dec 15, 1999	Apr	DISC		
>A>		@	0.05MG;0.5MG	N75406	001	Dec 15, 1999	Apr	DISC		
		OVRAL								
		@ AKRIMAX PHARMS	0.05MG;0.5MG	N16672	001		Mar	CAHN		
		ETHOTOIN								
		TABLET; ORAL								
		PEGANONE								
>A>		+ LUNDBECK INC	250MG	N10841	001		Apr	CAHN		
>A>		@	500MG	N10841	003		Apr	CAHN		
>D>		+ OVATION PHARMS	250MG	N10841	001		Apr	CAHN		
>D>		@	500MG	N10841	003		Apr	CAHN		
		ETOPOSIDE								
		CAPSULE; ORAL								
		ETOPOSIDE								
		+ GENPHARM	50MG	N75635	001	Sep 19, 2001	Feb	CRLD		

CAPSULE; ORAL
VEPESID
@ BRISTOL MYERS SQUIBB 50MG N19557 001 Dec 30, 1986 Feb DISC

EVEROLIMUS

TABLET; ORAL
AFINITOR
NOVARTIS 5MG N22334 001 Mar 30, 2009 Mar NEWA
\+ 10MG N22334 002 Mar 30, 2009 Mar NEWA

FAMOTIDINE

TABLET; ORAL
FAMOTIDINE
@ SANDOZ 20MG N75302 001 Apr 16, 2001 Mar DISC
@ 40MG N75302 002 Apr 16, 2001 Mar DISC

FEBUXOSTAT

TABLET; ORAL
ULORIC
TAKEDA PHARMS 40MG N21856 001 Feb 13, 2009 Feb NEWA
\+ 80MG N21856 002 Feb 13, 2009 Feb NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL
NALFON
@ PEDINOL EQ 300MG BASE N17604 002 Feb DISC
NALFON 200
\+ PEDINOL EQ 200MG BASE N17604 003 Feb CRLD
TABLET; ORAL
FENOPROFEN CALCIUM
@ SANDOZ EQ 600MG BASE N72396 001 Oct 17, 1988 Mar DISC

FLECAINIDE ACETATE

TABLET; ORAL
FLECAINIDE ACETATE
@ SANDOZ 50MG N76030 001 Oct 28, 2002 Mar DISC
@ 100MG N76030 002 Oct 28, 2002 Mar DISC
@ 150MG N76030 003 Oct 28, 2002 Mar DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION
FLUDARABINE PHOSPHATE
AP ACTAVIS TOTOWA 50MG/VIAL N78610 001 Feb 11, 2009 Feb NEWA

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL
AP HIKMA FARMACEUTICA 0.5MG/5ML (0.1MG/ML) N78527 001 Mar 23, 2009 Mar NEWA
AP 1MG/10ML (0.1MG/ML) N78527 002 Mar 23, 2009 Mar NEWA

FLUOCINOLONE ACETONIDE

OIL; TOPICAL
DERMA-SMOOTHE/FS
\+ HILL DERMAC 0.01% N19452 002 Nov 09, 2005 Feb NEWA

FLUOROURACIL

SOLUTION; TOPICAL

FLUOROPLEX

	@ ELORAC	1%	N16765	001		Feb	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1	ALEMBIC LTD	EQ 10MG BASE	N90223	001	Mar 19, 2009	Mar	NEWA
AB1		EQ 20MG BASE	N90223	002	Mar 19, 2009	Mar	NEWA
AB		EQ 40MG BASE	N90223	003	Mar 19, 2009	Mar	NEWA
AB1	BEIJING DOUBLE CRANE	EQ 10MG BASE	N76165	001	Feb 01, 2002	Mar	CAHN
AB1		EQ 20MG BASE	N76165	002	Feb 01, 2002	Mar	CAHN

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA	AUROBINDO PHARM	EQ 20MG BASE/5ML	N79209	001	Mar 20, 2009	Mar	NEWA

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

>D> AB	ALPHAPHARM	EQ 10MG BASE	N75755	001	Aug 02, 2001	Apr	CAHN
>D> +		EQ 20MG BASE	N75755	002	Aug 02, 2001	Apr	CAHN
>A> AB	MYLAN	EQ 10MG BASE	N75755	001	Aug 02, 2001	Apr	CAHN
>A> +		EQ 20MG BASE	N75755	002	Aug 02, 2001	Apr	CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

	@ SANDOZ	15MG	N71716	001	Jul 31, 1991	Mar	DISC
	@	30MG	N71717	001	Jul 31, 1991	Mar	DISC

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

	@ SANDOZ	50MG	N74448	001	Jul 28, 1995	Mar	DISC
	@	100MG	N74448	002	Jul 28, 1995	Mar	DISC

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

	@ IVAX PHARMS	25MG	N75898	001	Mar 12, 2001	Mar	DISC
	@	50MG	N75898	002	Mar 12, 2001	Mar	DISC
	@	100MG	N75898	003	Mar 12, 2001	Mar	DISC

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

AP	GENERAMEDIX	1.5GM/1.5ML (1GM/ML)	N79033	001	Apr 07, 2009	Mar	NEWA

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

	@ SANDOZ	10MG	N76188	001	Oct 08, 2004	Mar	DISC
	@	20MG	N76188	002	Oct 08, 2004	Mar	DISC
	@	40MG	N76188	003	Oct 08, 2004	Mar	DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

MONOPRIL-HCT

	@	BRISTOL MYERS SQUIBB	10MG;12.5MG	N20286	002	Nov 30, 1994	Feb	DISC
	@		20MG;12.5MG	N20286	001	Nov 30, 1994	Feb	DISC

GALANTAMINE HYDROBROMIDE

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

AA		ROXANE	4MG/ML	N78185	001	Jan 30, 2009	Jan	NEWA

RAZADYNE

AA	+	ORTHO MCNEIL JANSSEN	4MG/ML	N21224	001	Jun 22, 2001	Jan	CFTG

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

>D>	AB	ALPHAPHARM	EQ 4MG BASE	N77603	001	Aug 28, 2008	Apr	CAHN
>D>	AB		EQ 8MG BASE	N77603	002	Aug 28, 2008	Apr	CAHN
>D>	AB		EQ 12MG BASE	N77603	003	Aug 28, 2008	Apr	CAHN
>A>	AB	BEJING YABAO	EQ 4MG BASE	N77604	001	Feb 06, 2009	Apr	CAHN
>A>	AB		EQ 8MG BASE	N77604	002	Feb 06, 2009	Apr	CAHN
>A>	AB		EQ 12MG BASE	N77604	003	Feb 06, 2009	Apr	CAHN
>A>	AB	MYLAN	EQ 4MG BASE	N77603	001	Aug 28, 2008	Apr	CAHN
>A>	AB		EQ 8MG BASE	N77603	002	Aug 28, 2008	Apr	CAHN
>A>	AB		EQ 12MG BASE	N77603	003	Aug 28, 2008	Apr	CAHN
>D>	AB	PAR PHARM	EQ 4MG BASE	N77604	001	Feb 06, 2009	Apr	CAHN
	AB		EQ 4MG BASE	N77604	001	Feb 06, 2009	Jan	NEWA
>D>	AB		EQ 8MG BASE	N77604	002	Feb 06, 2009	Apr	CAHN
	AB		EQ 8MG BASE	N77604	002	Feb 06, 2009	Jan	NEWA
>D>	AB		EQ 12MG BASE	N77604	003	Feb 06, 2009	Apr	CAHN
	AB		EQ 12MG BASE	N77604	003	Feb 06, 2009	Jan	NEWA
	AB	ROXANE	EQ 4MG BASE	N77608	001	Feb 11, 2009	Jan	NEWA
	AB		EQ 8MG BASE	N77608	002	Feb 11, 2009	Jan	NEWA
	AB		EQ 12MG BASE	N77608	003	Feb 11, 2009	Jan	NEWA

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB	+	TEVA	5MG	N74388	003	Aug 29, 1995	Mar	CRLD

MICRONASE

	@	PHARMACIA AND UPJOHN	1.25MG	N17498	001	May 01, 1984	Mar	DISC
	@		2.5MG	N17498	002	May 01, 1984	Mar	DISC
	@		5MG	N17498	003	May 01, 1984	Mar	DISC

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA		WEST WARD	1MG	N40836	001	Mar 05, 2009	Feb	NEWA
AA			2MG	N40836	002	Mar 05, 2009	Feb	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>A>	AP	SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N78534	001	Apr 30, 2009	Apr	NEWA
>A>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N78531	001	Apr 30, 2009	Apr	NEWA
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N78531	002	Apr 30, 2009	Apr	NEWA

TABLET; ORAL
GRANISETRON HYDROCHLORIDE

	AB	DR REDDYS LABS LTD	EQ 1MG BASE	N78846	001	Feb 27, 2009	Feb	NEWA

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

>D>	AO	SANDOZ	EQ 50MG BASE/ML	N76463	001	Jun 24, 2005	Apr	DISC
>A>		@	EQ 50MG BASE/ML	N76463	001	Jun 24, 2005	Apr	DISC
>D>	AO		EQ 100MG BASE/ML	N76463	002	Jun 24, 2005	Apr	DISC
>A>		@	EQ 100MG BASE/ML	N76463	002	Jun 24, 2005	Apr	DISC

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

>D>	AP	SANDOZ	EQ 5MG BASE/ML	N76464	001	Sep 29, 2004	Apr	DISC
>A>		@	EQ 5MG BASE/ML	N76464	001	Sep 29, 2004	Apr	DISC

HEPARIN SODIUM

INJECTABLE; INJECTION
>D> HEPARIN LOCK FLUSH

>D>	AP	HOSPIRA	10 UNITS/ML	N88346	001	May 18, 1983	Apr	DISC
>A>		@	10 UNITS/ML	N88346	001	May 18, 1983	Apr	DISC

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS
SUPPRELIN LA

>A>	+	ENDO PHARM	50MG	N22058	001	May 03, 2007	Apr	CAHN
>D>	+	INDEVUS	50MG	N22058	001	May 03, 2007	Apr	CAHN

VANTAS

>A>	+	ENDO PHARM	50MG	N21732	001	Oct 12, 2004	Apr	CAHN
>D>	+	ENDO PHARMS	50MG	N21732	001	Oct 12, 2004	Apr	CAHN
	+		50MG	N21732	001	Oct 12, 2004	Mar	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
HYCODAN

		@ ENDO PHARMS	1.5MG/5ML;5MG/5ML	N05213	002	Jul 26, 1988	Feb	DISC

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	+	HI TECH PHARMA	1.5MG/5ML;5MG/5ML	N40613	001	Feb 08, 2008	Feb	CRLD

TABLET; ORAL
HYCODAN

		@ ENDO PHARMS	1.5MG;5MG	N05213	001	Jul 26, 1988	Feb	DISC

TUSSIGON

AA	+	KING PHARMS	1.5MG;5MG	N88508	001	Jul 30, 1985	Feb	CRLD

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HYDROCHLORIDE

AP		AKORN	20MG/ML	N40730	001	Apr 21, 2009	Mar	NEWA

TABLET; ORAL
HYDRALAZINE HYDROCHLORIDE

		@ SANDOZ	10MG	N83241	001		Mar	DISC
		@	25MG	N83560	001		Mar	DISC
		@	50MG	N83561	001		Mar	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

AB	IPCA LABS LTD	12.5MG	N79237	001	Apr 02, 2009	Mar		NEWA

SOLUTION; ORAL
HYDROCHLOROTHIAZIDE

	@ ROXANE	50MG/5ML	N88587	001	Jul 02, 1984	Mar		DISC

TABLET; ORAL
HYDROCHLOROTHIAZIDE

	@ SANDOZ	25MG	N87565	001	Mar 09, 1982	Mar		DISC
	@	50MG	N84912	001		Mar		DISC

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ SANDOZ	25MG;40MG	N71060	001	Aug 26, 1987	Mar		DISC
	@	25MG;80MG	N71061	001	Aug 26, 1987	Mar		DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	RANBAXY	12.5MG;EQ 10MG BASE	N78211	001	Mar 04, 2009	Feb		NEWA
AB		12.5MG;EQ 20MG BASE	N78211	002	Mar 04, 2009	Feb		NEWA
AB		25MG;EQ 20MG BASE	N78211	003	Mar 04, 2009	Feb		NEWA

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

	@ SANDOZ	25MG;25MG	N86881	001		Mar		DISC

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION; OPHTHALMIC
TERRA-CORTRIL

	@ PFIZER	1.5%;EQ 5MG BASE/ML	N61016	001		Feb		DISC

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL
PROCTOFOAM HC

>D>	BX	SCHWARZ PHARMA	1%;1%	N86195	001		Apr	CAHN
>A>	BX	UCB INC	1%;1%	N86195	001		Apr	CAHN

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL
CARMOL HC

>D>	AT	+ KENWOOD LABS	1%;10%	N80505	001		Apr	CAHN
>A>	AT	+ NYCOMED US	1%;10%	N80505	001		Apr	CAHN

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION
>A> DILAUDID

>A>		PURDUE PHARM PRODS	1MG/ML	N19034	003	Apr 30, 2009	Apr	NEWA
>A>			2MG/ML	N19034	004	Apr 30, 2009	Apr	NEWA
>A>			4MG/ML	N19034	005	Apr 30, 2009	Apr	NEWA

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

AB		BARR	500MG	N75143	001	Oct 16, 1998	Feb	CMFD

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	@	SANDOZ	10MG	N87869	001	Dec 20, 1982	Mar	DISC
	@		25MG	N87870	001	Dec 20, 1982	Mar	DISC
	@		50MG	N87871	001	Dec 20, 1982	Mar	DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

	@	SANDOZ	EQ 25MG HCL	N81127	001	Jun 28, 1991	Mar	DISC

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB	+	DR REDDYS LA	800MG	N75682	003	Nov 14, 2001	Feb	CRLD
	@	SANDOZ	300MG	N70734	001	Jun 12, 1986	Mar	DISC
	@		400MG	N70735	001	Jun 12, 1986	Mar	DISC
	@		600MG	N70736	001	Jun 12, 1986	Mar	DISC
	@		800MG	N72169	001	Dec 11, 1987	Mar	DISC
AB		SHASUN USA	400MG	N78329	001	Feb 05, 2009	Jan	NEWA
AB			600MG	N78329	002	Feb 05, 2009	Jan	NEWA
AB			800MG	N78329	003	Feb 05, 2009	Jan	NEWA
>D>		MOTRIN						
>D>		MCNEIL CONSUMER	300MG	N17463	003		Apr	DISC
>A>	@		300MG	N17463	003		Apr	DISC
	@		400MG	N17463	002		Feb	DISC
	@		600MG	N17463	004		Feb	DISC
	@		800MG	N17463	005	May 22, 1985	Feb	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

>A>	+	LUNDBECK INC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N21903	001	Apr 13, 2006	Apr	CAHN
>D>	+	OVATION PHARMS	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N21903	001	Apr 13, 2006	Apr	CAHN

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

	@	BAXTER HLTHCARE	1GM/VIAL	N19763	001	Dec 30, 1988	Feb	CAHN
	@		3GM/VIAL	N19763	002	Dec 30, 1988	Feb	CAHN

IFOSFAMIDE; MESNA

INJECTABLE; INJECTION

IFEX/MESNEX KIT

	+	BAXTER HLTHCARE	1GM/VIAL;100MG/ML	N19763	003	Oct 10, 1992	Feb	CAHN
	+		3GM/VIAL;100MG/ML	N19763	004	Oct 10, 1992	Feb	CAHN

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOCIN SR

AB	+	SANDOZ	75MG	N74464	001	May 28, 1998	Feb	CTEC

INDOMETHACIN

AB		AVANTHI INC	75MG	N79175	001	Mar 06, 2009	Feb	NEWA

SUSPENSION; ORAL

INDOCIN

	+	IROKO PHARMS	25MG/5ML	N18332	001	Oct 10, 1985	Mar	CAHN

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

>A>	AP	+	LUNDBECK INC	EQ 1MG BASE/VIAL	N18878	001	Jan 30, 1985	Apr	CAHN
>D>	AP	+	OVATION PHARMS	EQ 1MG BASE/VIAL	N18878	001	Jan 30, 1985	Apr	CAHN

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA SOLOSTAR

			SANOFI AVENTIS US	300 UNITS/3ML	N21629	003	Feb 24, 2009	Feb	NEWA

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

>D>	AN		IVAX PHARMS	0.02%	N75313	001	Feb 07, 2000	Apr	CAHN
>A>	AN		TEVA PARENTERAL	0.02%	N75313	001	Feb 07, 2000	Apr	CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

	AP		PHARMAFORCE	40MG/2ML (20MG/ML)	N90016	001	Jan 28, 2009	Mar	NEWA
	AP			40MG/2ML(20MG/ML)	N90016	001	Jan 28, 2009	Jan	NEWA
	AP			100MG/5ML (20MG/ML)	N90016	002	Jan 28, 2009	Mar	NEWA
	AP			100MG/5ML(20MG/ML)	N90016	002	Jan 28, 2009	Jan	NEWA

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

		@	SANDOZ	2.5MG	N86225	001	Feb 19, 1988	Mar	DISC
		@		5MG	N86222	001	Feb 19, 1988	Mar	DISC

KETOCONAZOLE

GEL; TOPICAL

XOLEGEL

		+	STIEFEL LABS INC	2%	N21946	001	Jul 28, 2006	Jan	CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

		@	SANDOZ	50MG	N74024	001	Dec 29, 1995	Mar	DISC
		@		75MG	N74024	002	Dec 29, 1995	Mar	DISC

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	APOTEX INC	25MG	N78625	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78625	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78625	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78625	004	Jan 27, 2009	Jan	NEWA
AB	AUROBINDO PHARMA	25MG	N78956	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78956	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78956	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78956	004	Jan 27, 2009	Jan	NEWA
AB	CADISTA PHARMS	25MG	N79132	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N79132	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N79132	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N79132	004	Jan 27, 2009	Jan	NEWA
AB	DR REDDYS LABS LTD	25MG	N76708	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N76708	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N76708	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N76708	004	Jan 27, 2009	Jan	NEWA
AB	GENPHARM ULC	25MG	N77428	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77428	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77428	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77428	004	Jan 27, 2009	Jan	NEWA
AB	MATRIX LABS LTD	25MG	N78443	001	Feb 11, 2009	Jan	NEWA
AB		100MG	N78443	002	Feb 11, 2009	Jan	NEWA
AB		150MG	N78443	003	Feb 11, 2009	Jan	NEWA
AB		200MG	N78443	004	Feb 11, 2009	Jan	NEWA
AB	MYLAN	25MG	N77420	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77420	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77420	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77420	004	Jan 27, 2009	Jan	NEWA
AB	ROXANE	25MG	N77392	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N77392	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N77392	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N77392	004	Jan 27, 2009	Jan	NEWA
AB	SANDOZ	25MG	N78645	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78645	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78645	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78645	004	Jan 27, 2009	Jan	NEWA
AB	TARO PHARM INDS	25MG	N78525	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78525	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78525	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78525	004	Jan 27, 2009	Jan	NEWA
AB	TORRENT PHARMS	25MG	N78947	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78947	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78947	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78947	004	Jan 27, 2009	Jan	NEWA
AB	UPSHER SMITH	25MG	N78310	001	Feb 04, 2009	Jan	NEWA
AB		100MG	N78310	002	Feb 04, 2009	Jan	NEWA
AB		150MG	N78310	003	Feb 04, 2009	Jan	NEWA
AB		200MG	N78310	004	Feb 04, 2009	Jan	NEWA
AB	WOCKHARDT	25MG	N78982	001	Jan 27, 2009	Jan	NEWA
AB		100MG	N78982	002	Jan 27, 2009	Jan	NEWA
AB		150MG	N78982	003	Jan 27, 2009	Jan	NEWA
AB		200MG	N78982	004	Jan 27, 2009	Jan	NEWA

TABLET; ORAL
LAMOTRIGINE

AB	ZYDUS PHARMS USA	25MG	N77633	001	Jan 27, 2009	Jan	NEWA
		50MG	N77633	002	Jan 27, 2009	Jan	NEWA
AB		100MG	N77633	003	Jan 27, 2009	Jan	NEWA
AB		150MG	N77633	004	Jan 27, 2009	Jan	NEWA
AB		200MG	N77633	005	Jan 27, 2009	Jan	NEWA
		250MG	N77633	006	Jan 27, 2009	Jan	NEWA

TABLET, CHEWABLE; ORAL
LAMOTRIGINE

AB	GLENMARK GENERICS	5MG	N79099	001	Feb 19, 2009	Feb	NEWA
AB		25MG	N79099	002	Feb 19, 2009	Feb	NEWA
AB	TARO	5MG	N79204	001	Feb 04, 2009	Jan	NEWA
AB		25MG	N79204	002	Feb 04, 2009	Jan	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LEUPROLIDE ACETATE

AP	SUN PHARMA GLOBAL	1MG/0.2ML	N78885	001	Mar 09, 2009	Feb	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN	DEY	EQ 0.25% BASE	N78309	001	Mar 20, 2009	Mar	NEWA

XOPENEX

AN	+ SEPRACOR	EQ 0.25% BASE	N20837	004	Jul 18, 2003	Mar	CFTG

LEVETIRACETAM

SOLUTION; ORAL
LEVETIRACETAM

AA	SILARX	100MG/ML	N90263	001	Apr 03, 2009	Mar	NEWA
AA	TARO	100MG/ML	N78774	001	Feb 10, 2009	Jan	NEWA

TABLET; ORAL
LEVETIRACETAM

AB	APOTEX INC	250MG	N78869	001	Mar 13, 2009	Mar	NEWA
AB		500MG	N78869	002	Mar 13, 2009	Mar	NEWA
AB		750MG	N78869	003	Mar 13, 2009	Mar	NEWA
AB		1GM	N78869	004	Mar 13, 2009	Mar	NEWA
AB	CIPLA LTD	250MG	N77319	001	Mar 20, 2009	Mar	NEWA
AB		500MG	N77319	002	Mar 20, 2009	Mar	NEWA
AB		750MG	N77319	003	Mar 20, 2009	Mar	NEWA
AB	GENPHARM ULC	250MG	N78731	001	Feb 10, 2009	Jan	NEWA
AB		500MG	N78731	002	Feb 10, 2009	Jan	NEWA
AB		750MG	N78731	003	Feb 10, 2009	Jan	NEWA
AB		1GM	N78731	004	Feb 10, 2009	Jan	NEWA
AB	SOLCO HLTHCARE	250MG	N78106	001	Feb 10, 2009	Jan	NEWA
AB		500MG	N78106	002	Feb 10, 2009	Jan	NEWA
AB		750MG	N78106	003	Feb 10, 2009	Jan	NEWA
AB		1GM	N78106	004	Feb 10, 2009	Jan	NEWA
AB	WATSON LABS FLORIDA	250MG	N77408	001	Mar 02, 2009	Feb	NEWA
AB		500MG	N77408	002	Mar 02, 2009	Feb	NEWA
AB		750MG	N77408	003	Mar 02, 2009	Feb	NEWA
>A> AB	ZYDUS PHARMS USA INC	250MG	N78918	001	Apr 29, 2009	Apr	NEWA
>A> AB		1GM	N78918	002	Apr 29, 2009	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL
KEPPRA XR

			UCB INC	500MG		N22285	001	Sep 12, 2008	Feb CRLD
		+		750MG		N22285	002	Feb 12, 2009	Feb NEWA

LEVOFLOXACIN

TABLET; ORAL
LEVAQUIN

>D>			ORTHO MCNEIL JANSSEN	250MG		N20634	001	Dec 20, 1996	Apr CFTG
>A>	AB			250MG		N20634	001	Dec 20, 1996	Apr CFTG
>D>				500MG		N20634	002	Dec 20, 1996	Apr CFTG
>A>	AB			500MG		N20634	002	Dec 20, 1996	Apr CFTG
>D>		+		750MG		N20634	003	Sep 08, 2000	Apr CFTG
>A>	AB	+		750MG		N20634	003	Sep 08, 2000	Apr CFTG
>A>			LEVOFLOXACIN						
>A>	AB		LUPIN	250MG		N78424	001	May 13, 2009	Apr NEWA
>A>	AB			500MG		N78424	002	May 13, 2009	Apr NEWA
>A>	AB			750MG		N78424	003	May 13, 2009	Apr NEWA

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL
LEVOTHYROXINE SODIUM

>D>	AB2, AB3		GENPHARM	0.025MG		N76752	001	Jun 16, 2005	Apr CAHN
>D>	AB2, AB3			0.05MG		N76752	002	Jun 16, 2005	Apr CAHN
>D>	AB2, AB3			0.075MG		N76752	003	Jun 16, 2005	Apr CAHN
>D>	AB2, AB3			0.088MG		N76752	004	Jun 16, 2005	Apr CAHN
>D>	AB2, AB3			0.1MG		N76752	005	Jun 16, 2005	Apr CAHN
>D>	AB2, AB3			0.112MG		N76752	006	Jun 16, 2005	Apr CAHN
>D>	AB2, AB3			0.125MG		N76752	007	Jun 16, 2005	Apr CAHN
>D>	AB2, AB3			0.15MG		N76752	008	Jun 16, 2005	Apr CAHN
>D>	AB2, AB3			0.175MG		N76752	009	Jun 16, 2005	Apr CAHN
>D>	AB2, AB3			0.2MG		N76752	010	Jun 16, 2005	Apr CAHN
>D>	AB2, AB3			0.3MG		N76752	011	Jun 16, 2005	Apr CAHN
>A>	AB2, AB3		MERCK KGAA	0.025MG		N76752	001	Jun 16, 2005	Apr CAHN
>A>	AB2, AB3			0.05MG		N76752	002	Jun 16, 2005	Apr CAHN
>A>	AB2, AB3			0.075MG		N76752	003	Jun 16, 2005	Apr CAHN
>A>	AB2, AB3			0.088MG		N76752	004	Jun 16, 2005	Apr CAHN
>A>	AB2, AB3			0.1MG		N76752	005	Jun 16, 2005	Apr CAHN
>A>	AB2, AB3			0.112MG		N76752	006	Jun 16, 2005	Apr CAHN
>A>	AB2, AB3			0.125MG		N76752	007	Jun 16, 2005	Apr CAHN
>A>	AB2, AB3			0.15MG		N76752	008	Jun 16, 2005	Apr CAHN
>A>	AB2, AB3			0.175MG		N76752	009	Jun 16, 2005	Apr CAHN
>A>	AB2, AB3			0.2MG		N76752	010	Jun 16, 2005	Apr CAHN

TABLET; ORAL
LEVOTHYROXINE SODIUM
>A> AB2, AB3 MERCK KGAA 0.3MG N76752 011 Jun 16, 2005 Apr CAHN

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER
>D> AP HOSPIRA 10% N88367 001 Jul 31, 1984 Apr DISC
>A> @ 10% N88367 001 Jul 31, 1984 Apr DISC
XYLOCAINE
>D> @ APP PHARMS 2% N06488 002 Apr CMFD
>A> AP + 2% N06488 002 Apr CMFD
>D> AP + DENTSPLY PHARM 2% N21380 001 Apr CTNA
>A> XYLOCAINE DENTAL
>A> AP + DENTSPLY PHARM 2% N21380 001 Apr CTNA

LINDANE

LOTION; TOPICAL
LINDANE
>D> @ AL AND S 1% N87313 001 Apr CAHN
>A> @ OLTA PHARMS 1% N87313 001 Apr CAHN
SHAMPOO; TOPICAL
LINDANE
AT + OLTA PHARMS 1% N87266 001 Jan CAHN

LIOTHYRONINE SODIUM

TABLET; ORAL
CYTOMEL
AB KING PHARMS EQ 0.005MG BASE N10379 001 Mar CFTG
AB EQ 0.025MG BASE N10379 002 Mar CTEC
AB + EQ 0.05MG BASE N10379 003 Mar CTEC
LIOTHYRONINE SODIUM
AB COASTAL PHARMS EQ 0.005MG BASE N90097 001 Mar 20, 2009 Mar NEWA
AB EQ 0.025MG BASE N90097 002 Mar 20, 2009 Mar NEWA
AB EQ 0.05MG BASE N90097 003 Mar 20, 2009 Mar NEWA

LITHIUM CARBONATE

CAPSULE; ORAL
LITHIUM CARBONATE
AB GLENMARK GENERICS 150MG N79139 001 Feb 03, 2009 Jan NEWA
AB 300MG N79139 002 Feb 03, 2009 Jan NEWA
AB 600MG N79139 003 Feb 03, 2009 Jan NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL
LOPERAMIDE HYDROCHLORIDE
@ SANDOZ 2MG N72993 001 Aug 28, 1992 Mar DISC

LORAZEPAM

CONCENTRATE; ORAL
>A> LORAZEPAM
>A> AA PADDOCK LABS 2MG/ML N79244 001 Apr 28, 2009 Apr NEWA
LORAZEPAM INTENSOL
>D> + ROXANE 2MG/ML N72755 001 Jun 28, 1991 Apr CFTG
>A> AA + 2MG/ML N72755 001 Jun 28, 1991 Apr CFTG

SOLUTION; ORAL
LORAZEPAM

		@ ROXANE	0.5MG/5ML	N74648	001	Mar 18, 1997	Mar	DISC

MALATHION

LOTION; TOPICAL
MALATHION

AT		SYNERX PHARMA	0.5%	N78743	001	Mar 06, 2009	Feb	NEWA

OVIDE

AT	+	TARO PHARMS NORTH	0.5%	N18613	001	Aug 02, 1982	Feb	CFTG

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
MUSTARGEN

>A>	+	LUNDBECK INC	10MG/VIAL	N06695	001		Apr	CAHN
>D>	+	OVATION PHARMS	10MG/VIAL	N06695	001		Apr	CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
ANTIVERT

AA	+	PFIZER	12.5MG	N10721	006		Jan	CAHN
AA	+		25MG	N10721	004		Jan	CAHN
AA	+		50MG	N10721	001	Jan 20, 1982	Jan	CAHN

MECLOFENAMATE SODIUM

CAPSULE; ORAL
MECLOFENAMATE SODIUM

		@ SANDOZ	EQ 50MG BASE	N72262	001	Nov 29, 1988	Mar	DISC
		@	EQ 100MG BASE	N72263	001	Nov 29, 1988	Mar	DISC

MELOXICAM

TABLET; ORAL
MELOXICAM

>A>	AB	BEJING YABAO	7.5MG	N77933	001	Jul 19, 2006	Apr	CAHN
>A>	AB		15MG	N77933	002	Jul 19, 2006	Apr	CAHN
>D>	AB	PAR PHARM	7.5MG	N77933	001	Jul 19, 2006	Apr	CAHN
>D>	AB		15MG	N77933	002	Jul 19, 2006	Apr	CAHN

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

	AA	ALEMBIC LTD	200MG	N90122	001	Feb 18, 2009	Feb	NEWA
	AA		400MG	N90122	002	Feb 18, 2009	Feb	NEWA
>A>		@ IVC INDS	400MG	N84153	001		Apr	CAHN
>D>		@ PHARMERAL	400MG	N84153	001		Apr	CAHN

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
SOLAGE

	+	STIEFEL LABS INC	2%;0.01%	N20922	001	Dec 10, 1999	Jan	CAHN

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/50M-21

>D>								
>D>	AB	WATSON LABS	0.05MG;1MG	N71539	001	Apr 12, 1988	Apr	DISC
>A>		@	0.05MG;1MG	N71539	001	Apr 12, 1988	Apr	DISC

TABLET; ORAL-21
NORETHINDRONE AND MESTRANOL

>D>	AB		WATSON LABS	0.05MG;1MG	N70758	001	Jul 01, 1988	Apr	DISC
>A>			@	0.05MG;1MG	N70758	001	Jul 01, 1988	Apr	DISC

NORINYL 1+50 21-DAY

>D>	AB	+	WATSON LABS	0.05MG;1MG	N13625	002		Apr	DISC
>A>			@	0.05MG;1MG	N13625	002		Apr	DISC

TABLET; ORAL-28
NORETHIN 1/50M-28

>D>	AB		WATSON LABS	0.05MG;1MG	N71540	001	Apr 12, 1988	Apr	DISC
>A>			@	0.05MG;1MG	N71540	001	Apr 12, 1988	Apr	DISC

NORETHINDRONE AND MESTRANOL

>D>	AB		WATSON LABS	0.05MG;1MG	N70759	001	Jul 01, 1988	Apr	DISC
>A>			@	0.05MG;1MG	N70759	001	Jul 01, 1988	Apr	DISC

NORINYL 1+50 28-DAY

>D>	AB		WATSON LABS	0.05MG;1MG	N16659	001		Apr	CRLD
>A>		+		0.05MG;1MG	N16659	001		Apr	CRLD

ORTHO-NOVUM 1/50 28

>D>	AB		ORTHO MCNEIL JANSSEN	0.05MG;1MG	N16709	001		Apr	DISC
>A>			@	0.05MG;1MG	N16709	001		Apr	DISC

METAPROTERENOL SULFATE

SOLUTION; INHALATION
ALUPENT

			@ BOEHRINGER INGELHEIM	0.4%	N18761	002	Oct 10, 1986	Feb	DISC
			@	0.6%	N18761	001	Jun 30, 1983	Feb	DISC

METFORMIN HYDROCHLORIDE

TABLET; ORAL
METFORMIN HYDROCHLORIDE

	AB		ALVOGEN	500MG	N76033	001	Jan 24, 2002	Jan	CAHN
	AB			850MG	N76033	002	Jan 24, 2002	Jan	CAHN
	AB			1GM	N76033	003	Jan 24, 2002	Jan	CAHN
>D>	AB		AMNEAL PHARM	500MG	N77853	001	Jul 28, 2006	Apr	CAHN
>D>	AB			850MG	N77853	002	Jul 28, 2006	Apr	CAHN
>D>	AB			1GM	N77853	003	Jul 28, 2006	Apr	CAHN
>A>	AB		PROVIDENT PHARM	500MG	N77853	001	Jul 28, 2006	Apr	CAHN
>A>	AB			850MG	N77853	002	Jul 28, 2006	Apr	CAHN
>A>	AB			1GM	N77853	003	Jul 28, 2006	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

			@ SANDOZ	500MG	N76223	001	Dec 14, 2004	Mar	DISC

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL
DESOXYN

>A>		+	LUNDBECK INC	5MG	N05378	002		Apr	CAHN
>D>		+	OVATION PHARMS	5MG	N05378	002		Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL
DESOXYN

>A>			@ LUNDBECK INC	5MG	N05378	004		Apr	CAHN
>A>			@	10MG	N05378	003		Apr	CAHN
>A>			@	15MG	N05378	005		Apr	CAHN
>D>			@ OVATION PHARMS	5MG	N05378	004		Apr	CAHN
>D>			@	10MG	N05378	003		Apr	CAHN
>D>			@	15MG	N05378	005		Apr	CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

@	SOLCO HLTHCARE	500MG	N86989	001		Jan	CAHN
@		750MG	N86988	001		Jan	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	EBEWE PARENTA	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	N90039	001	Mar 31, 2009	Mar	NEWA
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	N90039	002	Mar 31, 2009	Mar	NEWA
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N90029	001	Mar 31, 2009	Mar	NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

	ABBOTT	2.5MG	N12524	001		Mar	CTEC

METHYCLOTHIAZIDE

@	SANDOZ	2.5MG	N89835	001	Aug 18, 1988	Mar	DISC
@		5MG	N89837	001	Aug 18, 1988	Mar	DISC

METHYLDOPA

TABLET; ORAL

METHYLDOPA

@	SANDOZ	125MG	N71700	001	Mar 02, 1988	Mar	DISC
@		250MG	N18934	001	Jun 29, 1984	Mar	DISC
@		500MG	N18934	002	Jun 29, 1984	Mar	DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB	SANDOZ	40MG/ML	N40719	001	Jan 29, 2009	Jan	NEWA
AB		40MG/ML	N40794	001	Mar 05, 2009	Feb	NEWA
AB		80MG/ML	N40719	002	Jan 29, 2009	Jan	NEWA
AB		80MG/ML	N40794	002	Mar 05, 2009	Feb	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	VISTAPHARM	EQ 5MG BASE/5ML	N75051	001	Jan 26, 2001	Mar	CMFD

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@	SANDOZ	EQ 5MG BASE	N74478	001	Oct 05, 1995	Mar	DISC
@		EQ 10MG BASE	N72215	001	Jan 30, 1990	Mar	DISC

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

@	SOLCO HLTHCARE	50MG	N74453	001	Apr 27, 1995	Jan	CAHN
@		100MG	N74453	002	Apr 27, 1995	Jan	CAHN

METRONIDAZOLE

TABLET; ORAL

METRONIDAZOLE

AB	ALEMBIC LTD	250MG	N79067	001	Mar 13, 2009	Mar	NEWA
AB		500MG	N79067	002	Mar 13, 2009	Mar	NEWA
	@ SANDOZ	250MG	N18740	001	Oct 22, 1982	Mar	DISC
	@	500MG	N18740	002	Oct 22, 1982	Mar	DISC

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

@ SANDOZ	150MG	N74450	001	May 16, 1996	Mar	DISC
@	200MG	N74450	002	May 16, 1996	Mar	DISC
@	250MG	N74450	003	May 16, 1996	Mar	DISC

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+	STIEFEL LABS INC	0.25%;81.35%;15%	N21026	001	Feb 16, 2006	Jan	CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

	CYPRESS BIOSCIENCE	12.5MG	N22256	001	Jan 14, 2009	Jan	NEWA
		25MG	N22256	002	Jan 14, 2009	Jan	NEWA
		50MG	N22256	003	Jan 14, 2009	Jan	NEWA
+		100MG	N22256	004	Jan 14, 2009	Jan	NEWA

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	BARR	EQ 45MG BASE	N65485	001	Mar 17, 2009	Mar	NEWA
AB		EQ 90MG BASE	N65485	002	Mar 17, 2009	Mar	NEWA
AB		EQ 135MG BASE	N65485	003	Mar 17, 2009	Mar	NEWA
AB	IMPAX LABS INC	EQ 45MG BASE	N90024	001	Feb 03, 2009	Jan	NEWA
AB		EQ 90MG BASE	N90024	002	Feb 03, 2009	Jan	NEWA
AB		EQ 135MG BASE	N90024	003	Feb 03, 2009	Jan	NEWA

SOLODYN

AB	MEDICIS	EQ 45MG BASE	N50808	001	May 08, 2006	Jan	CFTG
AB		EQ 90MG BASE	N50808	002	May 08, 2006	Jan	CFTG
AB +		EQ 135MG BASE	N50808	003	May 08, 2006	Jan	CFTG

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	GENERAMEDIX	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N78980	001	Apr 13, 2009	Mar	NEWA
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	N78980	002	Apr 13, 2009	Mar	NEWA

>A> MIVACURIUM CHLORIDE

>A> INJECTABLE; INJECTION

>A> MIVACURIUM CHLORIDE

>A> +	EBEWE PARENTA	EQ 2MG BASE/ML	N78562	001	Apr 30, 2009	Apr	NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

+		ACTAVIS ELIZABETH	10MG	N20616	008	Apr 20, 2007	Feb	CRLD
+			80MG	N20616	006	Oct 27, 2006	Feb	CRLD

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

>D>	AB	AB GENERICS	15MG	N74862	001	Jul 07, 1998	Apr	DISC
>A>		@	15MG	N74862	001	Jul 07, 1998	Apr	DISC
>D>	AB		30MG	N74862	002	Jul 07, 1998	Apr	DISC
>A>		@	30MG	N74862	002	Jul 07, 1998	Apr	DISC
>D>	AB		60MG	N74862	003	Jul 07, 1998	Apr	DISC
>A>		@	60MG	N74862	003	Jul 07, 1998	Apr	DISC
>D>	AB		100MG	N74769	001	Jul 02, 1998	Apr	DISC
>A>		@	100MG	N74769	001	Jul 02, 1998	Apr	DISC
>D>	AB		200MG	N74769	002	Jul 02, 1998	Apr	DISC
>A>		@	200MG	N74769	002	Jul 02, 1998	Apr	DISC

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

>A>	AB	ACCORD HLTHCARE INC	250MG	N90253	001	May 04, 2009	Apr	NEWA
>A>	AB	APOTEX CORP	250MG	N90419	001	Apr 22, 2009	Apr	NEWA
>A>	AB	MYLAN	250MG	N65520	001	May 04, 2009	Apr	NEWA
>A>	AB	TEVA PHARMS	250MG	N65491	001	May 06, 2009	Apr	NEWA
>A>	AB	ZYDUS PHARMS USA INC	250MG	N65433	001	May 04, 2009	Apr	NEWA

TABLET; ORAL

MYCOPHENOLATE MOFETIL

>A>	AB	ACCORD HLTHCARE	500MG	N65416	001	May 04, 2009	Apr	NEWA
>A>	AB	APOTEX	500MG	N90499	001	Apr 22, 2009	Apr	NEWA
>A>	AB	MYLAN	500MG	N65521	001	May 04, 2009	Apr	NEWA
>A>	AB	TEVA PHARMS	500MG	N65457	001	May 04, 2009	Apr	NEWA
>A>	AB	ZYDUS PHARMS USA INC	500MG	N65477	001	May 04, 2009	Apr	NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

	AB	ACTAVIS ELIZABETH	500MG	N79093	001	Feb 27, 2009	Feb	NEWA
	AB		750MG	N79093	002	Feb 27, 2009	Feb	NEWA
		@ SANDOZ	500MG	N75590	001	Feb 25, 2002	Mar	DISC
		@	750MG	N75590	002	Feb 25, 2002	Mar	DISC

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

+		STAT TRADE	EQ 375MG BASE	N20353	001	Jan 05, 1996	Mar	CTEC
+			EQ 500MG BASE	N20353	002	Jan 05, 1996	Mar	CTEC

NAPROXEN SODIUM

		@ WATSON LABS FLORIDA	EQ 375MG BASE	N75416	002	Apr 23, 2003	Mar	DISC
		@	EQ 500MG BASE	N75416	001	Aug 27, 2002	Mar	DISC

NIFEDIPINE

CAPSULE; ORAL

PROCARDIA

>D>	AB	PFIZER	10MG	N18482	001		Apr	CRLD

CAPSULE; ORAL
PROCARDIA

>A>	AB	+	PFIZER	10MG	N18482	001			Apr	CRLD
>D>	AB	+		20MG	N18482	002	Jul 24, 1986		Apr	DISC
>A>			@	20MG	N18482	002	Jul 24, 1986		Apr	DISC

NIMODIPINE

CAPSULE; ORAL
NIMODIPINE

	AB	+	BARR	30MG	N77811	001	May 02, 2007		Mar	CRLD

NIMOTOP

			@ BAYER PHARMS	30MG	N18869	001	Dec 28, 1988		Feb	DISC

NITISINONE

CAPSULE; ORAL
ORFADIN

			RARE DIS	2MG	N21232	001	Jan 18, 2002		Mar	CAHN
				5MG	N21232	002	Jan 18, 2002		Mar	CAHN
		+		10MG	N21232	003	Jan 18, 2002		Mar	CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN

			@ SANDOZ	25MG	N74336	001	Jan 25, 1995		Mar	DISC
			@	50MG	N74336	002	Jan 25, 1995		Mar	DISC
			@	100MG	N74336	003	Jan 25, 1995		Mar	DISC

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

	AT		FDC LTD	0.3%	N78559	001	Feb 25, 2009		Feb	NEWA

TABLET; ORAL
FLOXIN

			@ ORTHO MCNEIL JANSSEN	200MG	N19735	001	Dec 28, 1990		Mar	DISC
			@	300MG	N19735	002	Dec 28, 1990		Mar	DISC
			@	400MG	N19735	003	Dec 28, 1990		Mar	DISC

OLSALAZINE SODIUM

CAPSULE; ORAL
DIPENTUM

>A>		+	ALAVEN PHARM	250MG	N19715	001	Jul 31, 1990		Apr	CAHN
>D>		+	UCB INC	250MG	N19715	001	Jul 31, 1990		Apr	CAHN

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

	AB		DR REDDYS LABS	40MG	N78490	001	Apr 17, 2009		Mar	NEWA
	AB		DR REDDYS LABS LTD	10MG	N78693	001	Mar 16, 2009		Mar	NEWA
	AB			20MG	N78693	002	Mar 16, 2009		Mar	NEWA
	AB		KREMERS URBAN DEV	40MG	N75410	003	Jan 23, 2009		Jan	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

	AP		BEDFORD LABS	EQ 0.64MG BASE/ML	N78291	001	Apr 13, 2009		Mar	NEWA

OXACILLIN SODIUM

INJECTABLE; INJECTION
OXACILLIN SODIUM

>D>		MARSAM PHARMS LLC	EQ 250MG BASE/VIAL	N62856	001	Oct 26, 1988	Apr	DISC
>D>			EQ 500MG BASE/VIAL	N62856	002	Oct 26, 1988	Apr	DISC
>D>	AP		EQ 1GM BASE/VIAL	N62856	003	Oct 26, 1988	Apr	DISC
>D>	AP		EQ 2GM BASE/VIAL	N62856	004	Oct 26, 1988	Apr	DISC
>D>			EQ 4GM BASE/VIAL	N62856	005	Oct 26, 1988	Apr	DISC
>A>		@ WATSON LABS	EQ 250MG BASE/VIAL	N62856	001	Oct 26, 1988	Apr	DISC
>A>		@	EQ 500MG BASE/VIAL	N62856	002	Oct 26, 1988	Apr	DISC
>A>		@	EQ 1GM BASE/VIAL	N62856	003	Oct 26, 1988	Apr	DISC
>A>		@	EQ 2GM BASE/VIAL	N62856	004	Oct 26, 1988	Apr	DISC
>A>		@	EQ 4GM BASE/VIAL	N62856	005	Oct 26, 1988	Apr	DISC

OXAPROZIN

TABLET; ORAL
OXAPROZIN

		@ SANDOZ	600MG	N75850	001	Apr 27, 2001	Mar	DISC

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL
GELNIQUE

	+	WATSON LABS	10%(100MG/PACKET)	N22204	001	Jan 27, 2009	Mar	CTNA

OXYBUTYNIN CHLORIDE

	+	WATSON LABS	10%(100MG/PACKET)	N22204	001	Jan 27, 2009	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
OXYBUTYIN CHLORIDE

AB		OSMOTICA PHARM	5MG	N78503	001	Feb 04, 2009	Jan	NEWA
AB			10MG	N78503	002	Feb 04, 2009	Jan	NEWA
AB			15MG	N78503	003	Feb 04, 2009	Jan	NEWA

OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE HYDROCHLORIDE

AB		SUN PHARM INDS INC	5MG	N90659	001	Apr 10, 2009	Mar	NEWA
AB			15MG	N90659	002	Apr 10, 2009	Mar	NEWA
AB			30MG	N90659	003	Apr 10, 2009	Mar	NEWA
AB		VINTAGE PHARMS	5MG	N77712	003	Mar 02, 2009	Mar	NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP		GENERAMEDIX	30MG/VIAL	N78300	001	Mar 10, 2009	Feb	NEWA
AP			90MG/VIAL	N78300	002	Mar 10, 2009	Feb	NEWA

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE; ORAL
CREON

>A>		SOLVAY	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N20725	001	Apr 30, 2009	Apr	NEWA
>A>			60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N20725	002	Apr 30, 2009	Apr	NEWA
>A>	+		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N20725	003	Apr 30, 2009	Apr	NEWA

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

>D>	AP	HOSPIRA	2MG/ML	N72321	001	Jan 19, 1989	Apr	DISC
>A>		@	2MG/ML	N72321	001	Jan 19, 1989	Apr	DISC

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

	AB	KUDCO IRELAND	EQ 20MG BASE	N78281	001	Mar 17, 2009	Mar	NEWA
	AB		EQ 40MG BASE	N78281	002	Mar 17, 2009	Mar	NEWA

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN-VK

>D>	AA	TEVA	EQ 250MG BASE/5ML	N60456	002		Apr	CRLD
>A>	AA	+	EQ 250MG BASE/5ML	N60456	002		Apr	CRLD

VEETIDS

		@ APOTHECON	EQ 125MG BASE/5ML	N61410	001		Mar	DISC
		@	EQ 250MG BASE/5ML	N61410	002		Mar	DISC

PHENYTOIN

SUSPENSION; ORAL

PHENYTOIN

>D>	AB	MORTON GROVE	125MG/5ML	N40420	001	Apr 19, 2002	Apr	CAHN
>A>	AB	WOCKHARDT EU	125MG/5ML	N40420	001	Apr 19, 2002	Apr	CAHN

PHENYTOIN SODIUM

CAPSULE; ORAL

PROMPT PHENYTOIN SODIUM

		@ IVAX PHARMS	100MG PROMPT	N80259	001		Jan	DISC

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

>A>	AB	LANNETT	7.5MG	N77220	002	May 06, 2009	Apr	NEWA

PINDOLOL

TABLET; ORAL

PINDOLOL

		@ SANDOZ	5MG	N73608	001	Mar 29, 1993	Mar	DISC
		@	10MG	N73609	001	Mar 29, 1993	Mar	DISC

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

	AA	GAVIS PHARMS	17GM/SCOOPFUL	N77736	001	May 26, 2006	Jan	CAHN
		@ TEVA PHARMS	17GM/SCOOPFUL	N77445	001	May 04, 2006	Jan	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

GOLYTELY

	+	BRAINTREE	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N19011	001	Jul 13, 1984	Mar	CTEC

		FOR SUSPENSION; ORAL							
		CO-LAV							
		@ BOCA PHARMA	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N73428	001	Jan 28, 1992	Mar	DISC	
		GO-EVAC							
		@ BOCA PHARMA	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N73433	001	Apr 28, 1992	Mar	DISC	
	POTASSIUM CHLORIDE								
		CAPSULE, EXTENDED RELEASE; ORAL							
		MICRO-K							
		@ KV PHARM	8MEQ	N18238	001		Feb	DISC	
		MICRO-K 10							
		@ KV PHARM	10MEQ	N18238	002	May 14, 1984	Feb	DISC	
		POTASSIUM CHLORIDE							
		@ KV PHARM	10MEQ	N70980	001	Feb 17, 1987	Feb	DISC	
		WATSON LABS FLORIDA	8MEQ	N77419	001	Jun 02, 2008	Feb	CTEC	
	+		10MEQ	N77419	002	Jun 02, 2008	Feb	CRLD	
		INJECTABLE; INJECTION							
		POTASSIUM CHLORIDE							
>D>	+	HOSPIRA	1.5MEQ/ML	N83345	001		Apr	DISC	
>A>		@	1.5MEQ/ML	N83345	001		Apr	DISC	
		TABLET, EXTENDED RELEASE; ORAL							
		POTASSIUM CHLORIDE							
AB	+	WATSON LABS FLORIDA	10MEQ	N75604	001	Apr 10, 2002	Jan	CRLD	
	PRAZOSIN HYDROCHLORIDE								
		CAPSULE; ORAL							
		PRAZOSIN HYDROCHLORIDE							
		@ SANDOZ	EQ 1MG BASE	N72576	001	May 16, 1989	Mar	DISC	
		@	EQ 2MG BASE	N72577	001	May 16, 1989	Mar	DISC	
		@	EQ 5MG BASE	N72578	001	May 16, 1989	Mar	DISC	
	PREDNISOLONE SODIUM PHOSPHATE								
		SOLUTION; ORAL							
		PREDNISOLONE SODIUM PHOSPHATE							
AA		AMNEAL PHARMS	EQ 15MG BASE/5ML	N78345	001	Mar 10, 2009	Feb	NEWA	
		SOLUTION/DROPS; OPHTHALMIC							
		PREDNISOLONE SODIUM PHOSPHATE							
>D>	+	BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	N40065	001	Jul 29, 1994	Apr	DISC	
>A>		@	EQ 0.11% PHOSPHATE	N40065	001	Jul 29, 1994	Apr	DISC	
	PREDNISONE								
		TABLET; ORAL							
		PREDNISONE							
		@ SANDOZ	10MG	N89983	001	Jan 12, 1989	Mar	DISC	
		@	50MG	N89984	001	Jan 12, 1989	Mar	DISC	
	PRILOCAINE HYDROCHLORIDE								
		INJECTABLE; INJECTION							
>D>		CITANEST PLAIN							
>D>	+	DENTSPLY PHARM	4%	N21382	001		Apr	CTNA	
>A>		CITANEST PLAIN DENTAL							
>A>	+	DENTSPLY PHARM	4%	N21382	001		Apr	CTNA	

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE

AA	SUN PHARM INDS INC	6.25MG/5ML	N40891	001	Mar 13, 2009	Mar	NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
DOLENE

AA	HERITAGE PHARMS INC	65MG	N80530	001		Mar	CMFD

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PROPRANOLOL HYDROCHLORIDE

AB	UPSHER SMITH	60MG	N78311	001	Mar 06, 2009	Feb	NEWA
AB		80MG	N78311	002	Mar 06, 2009	Feb	NEWA
AB		120MG	N78311	003	Mar 06, 2009	Feb	NEWA
AB		160MG	N78311	004	Mar 06, 2009	Feb	NEWA

TABLET; ORAL
PROPRANOLOL HYDROCHLORIDE

@	SANDOZ	10MG	N70663	001	Jun 13, 1986	Mar	DISC
@		20MG	N70664	001	Jun 13, 1986	Mar	DISC
@		40MG	N70665	001	Jun 13, 1986	Mar	DISC
@		60MG	N70666	001	Oct 10, 1986	Mar	DISC
@		80MG	N70667	001	Jun 13, 1986	Mar	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL
CORPHED

@	SANDOZ	60MG;2.5MG	N88602	001	Apr 11, 1985	Mar	DISC

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

+	SANDOZ	60MG;2.5MG	N88193	001	May 17, 1983	Mar	CTEC

RAMIPRIL

CAPSULE; ORAL
RAMIPRIL

AB	RANBAXY	5MG	N78849	001	Mar 06, 2009	Feb	NEWA
AB		10MG	N78849	002	Mar 06, 2009	Feb	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
RANITIDINE HYDROCHLORIDE

>D> AP	BEDFORD	EQ 25MG BASE/ML	N74764	001	Nov 19, 2004	Apr	DISC
>A>	@	EQ 25MG BASE/ML	N74764	001	Nov 19, 2004	Apr	DISC

SYRUP; ORAL
RANITIDINE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 15MG BASE/ML	N78312	001	Sep 02, 2008	Feb	CTNA
AA	WOCKHARDT	EQ 15MG BASE/ML	N79212	001	Feb 23, 2009	Feb	NEWA

RISPERIDONE

SOLUTION; ORAL
RISPERDAL

AA +	ORTHO MCNEIL JANSSEN	1MG/ML	N20588	001	Jun 10, 1996	Jan	CFTG

RISPERIDONE

AA	TEVA	1MG/ML	N76440	001	Jan 30, 2009	Jan	NEWA

TABLET; ORAL
RISPERIDONE

AB	CADISTA PHARMS	0.25MG	N78828	001	Mar 23, 2009	Mar	NEWA
AB		0.5MG	N78828	002	Mar 23, 2009	Mar	NEWA
AB		1MG	N78828	003	Mar 23, 2009	Mar	NEWA
AB		2MG	N78828	004	Mar 23, 2009	Mar	NEWA
AB		3MG	N78828	005	Mar 23, 2009	Mar	NEWA
AB		4MG	N78828	006	Mar 23, 2009	Mar	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

AB	ORTHO MCNEIL JANSSEN	0.5MG	N21444	001	Apr 02, 2003	Feb	CFTG
AB		2MG	N21444	003	Apr 02, 2003	Feb	CFTG
>D>		3MG	N21444	004	Dec 23, 2004	Apr	CFTG
>A> AB		3MG	N21444	004	Dec 23, 2004	Apr	CFTG
>D>		4MG	N21444	005	Dec 23, 2004	Apr	CFTG
>A> AB		4MG	N21444	005	Dec 23, 2004	Apr	CFTG

RISPERIDONE

AB	DR REDDYS LABS LTD	0.5MG	N77328	001	Feb 24, 2009	Feb	NEWA
AB		2MG	N77328	003	Feb 24, 2009	Feb	NEWA
>A>	KALI LABS	0.25MG	N77494	001	Apr 30, 2009	Apr	NEWA
>A> AB		0.5MG	N77494	002	Apr 30, 2009	Apr	NEWA
>A> AB		2MG	N77494	004	Apr 30, 2009	Apr	NEWA
>A> AB		3MG	N77494	005	Apr 30, 2009	Apr	NEWA
>A> AB		4MG	N77494	006	Apr 30, 2009	Apr	NEWA
>A> AB	ZYDUS PHARMS USA	0.5MG	N78516	001	May 01, 2009	Apr	NEWA
>A> AB		2MG	N78516	003	May 01, 2009	Apr	NEWA

>D> RITODRINE HYDROCHLORIDE

>D> INJECTABLE; INJECTION
>D> RITODRINE HYDROCHLORIDE

>D> +	HOSPIRA	10MG/ML	N71618	001	Feb 28, 1991	Apr	DISC
>A> @		10MG/ML	N71618	001	Feb 28, 1991	Apr	DISC
>D> +		15MG/ML	N71619	001	Feb 28, 1991	Apr	DISC
>A> @		15MG/ML	N71619	001	Feb 28, 1991	Apr	DISC

>D> RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

>D> +	HOSPIRA	30MG/100ML	N71438	001	Jan 22, 1991	Apr	DISC
>A> @		30MG/100ML	N71438	001	Jan 22, 1991	Apr	DISC

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
ROPINIROLE HYDROCHLORIDE

>A> AB	HUAHAI US INC	EQ 0.25MG BASE	N78110	001	May 05, 2008	Apr	CAHN
>A> AB		EQ 0.5MG BASE	N78110	002	May 05, 2008	Apr	CAHN
>A> AB		EQ 1MG BASE	N78110	003	May 05, 2008	Apr	CAHN
>A> AB		EQ 2MG BASE	N78110	004	May 05, 2008	Apr	CAHN
>A> AB		EQ 3MG BASE	N78110	005	May 05, 2008	Apr	CAHN
>A> AB		EQ 4MG BASE	N78110	006	May 05, 2008	Apr	CAHN
>D> AB	PAR PHARM	EQ 0.25MG BASE	N78110	001	May 05, 2008	Apr	CAHN
>D> AB		EQ 0.5MG BASE	N78110	002	May 05, 2008	Apr	CAHN
>D> AB		EQ 1MG BASE	N78110	003	May 05, 2008	Apr	CAHN
>D> AB		EQ 2MG BASE	N78110	004	May 05, 2008	Apr	CAHN
>D> AB		EQ 3MG BASE	N78110	005	May 05, 2008	Apr	CAHN
>D> AB		EQ 4MG BASE	N78110	006	May 05, 2008	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL
REQUIP XL

>A>	SMITHKLINE BEECHAM	EQ 6MG BASE	N22008	006	Apr 10, 2009	Apr	NEWA

SELEGILINE HYDROCHLORIDE

TABLET; ORAL
SELEGILINE HYDROCHLORIDE

>D>	AB	ENDO PHARMS	5MG	N74565	001	Aug 02, 1996	Apr	DISC
>A>		@	5MG	N74565	001	Aug 02, 1996	Apr	DISC
>D>	AB	SIEGFRIED	5MG	N74672	001	Apr 01, 1997	Apr	DISC
>A>		@	5MG	N74672	001	Apr 01, 1997	Apr	DISC

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

AB	AUSTARPHARMA LLC	EQ 25MG BASE	N78677	001	Mar 04, 2009	Feb	NEWA
AB		EQ 50MG BASE	N78677	002	Mar 04, 2009	Feb	NEWA
AB		EQ 100MG BASE	N78677	003	Mar 04, 2009	Feb	NEWA

SIMVASTATIN

TABLET; ORAL
SIMVASTATIN

AB	LUPIN	5MG	N78103	005	Apr 14, 2009	Mar	NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
KALEXATE

AA	KVK TECH	454GM/BOT	N40905	001	Mar 30, 2009	Mar	NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
NORDITROPIN NORDIFLEX

	NOVO NORDISK INC	30MG/3ML	N21148	007	Mar 10, 2009	Mar	NEWA

STANOZOLOL

TABLET; ORAL
WINSTROL

	@ LUNDBECK INC	2MG	N12885	001	May 14, 1984	Mar	CAHN

STAVUDINE

FOR SOLUTION; ORAL
STAVUDINE

AA	CIPLA LTD	1MG/ML	N78030	001	Mar 20, 2009	Mar	NEWA

SUCCIMER

CAPSULE; ORAL
CHEMET

+	LUNDBECK INC	100MG	N19998	002	Jan 30, 1991	Mar	CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL
SULFACETAMIDE SODIUM

AB	PERRIGO CO TENNESSEE	10%	N78649	001	Mar 23, 2009	Mar	NEWA

SOLUTION/DROPS; OPHTHALMIC

>D>	SULF-10							
>D>	AT	NOVARTIS	10%	N80025	001		Apr	DISC
>A>		@	10%	N80025	001		Apr	DISC
	SULFACETAMIDE SODIUM							
>D>	+	ALCON	30%	N89068	001	May 05, 1987	Apr	DISC

		SOLUTION/DROPS; OPHTHALMIC							
		SULFACETAMIDE SODIUM							
>A>		@ ALCON	30%		N89068	001	May 05, 1987	Apr	DISC
		SULFAMETHOXAZOLE; TRIMETHOPRIM							
		TABLET; ORAL							
		SULFAMETHOPRIM							
	AB	PAR PHARM	400MG;80MG		N70022	001	Feb 15, 1985	Mar	CMFD
		SULFAMETHOPRIM-DS							
	AB	PAR PHARM	800MG;160MG		N70032	001	Feb 15, 1985	Mar	CMFD
		SULFAMETHOXAZOLE AND TRIMETHOPRIM							
		@ SANDOZ	800MG;160MG		N70890	001	Nov 13, 1986	Mar	DISC
		SULINDAC							
		TABLET; ORAL							
		SULINDAC							
		@ SANDOZ	150MG		N72712	001	Aug 30, 1991	Mar	DISC
		@	200MG		N72713	001	Aug 30, 1991	Mar	DISC
		SUMATRIPTAN SUCCINATE							
		INJECTABLE; SUBCUTANEOUS							
		IMITREX							
	AP	+ GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N20080	001	Dec 28, 1992	Jan	CFTG
		SUMATRIPTAN SUCCINATE							
	AP	APP PHARMS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N79242	001	Mar 02, 2009	Feb	NEWA
	AP	BEDFORD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N79123	001	Feb 06, 2009	Jan	NEWA
	AP	SANDOZ	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N78067	002	Feb 06, 2009	Jan	NEWA
	AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N78067	001	Feb 06, 2009	Jan	NEWA
	AP	TEVA PARENTERAL	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N78318	001	Feb 06, 2009	Jan	NEWA
	AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N78318	002	Feb 06, 2009	Jan	NEWA
	AP		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N77907	001	Feb 06, 2009	Jan	NEWA
	AP	WOCKHARDT	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N78593	001	Feb 06, 2009	Jan	NEWA
		TABLET; ORAL							
		IMITREX							
	AB	GLAXOSMITHKLINE	EQ 25MG BASE		N20132	002	Jun 01, 1995	Jan	CFTG
	AB		EQ 50MG BASE		N20132	003	Jun 01, 1995	Jan	CFTG
	AB	+	EQ 100MG BASE		N20132	001	Jun 01, 1995	Jan	CFTG
		SUMATRIPTAN SUCCINATE							
	AB	RANBAXY	EQ 100MG BASE		N76572	001	Feb 09, 2009	Jan	NEWA
	AB	TEVA	EQ 25MG BASE		N76840	001	Feb 09, 2009	Jan	NEWA
	AB		EQ 50MG BASE		N76840	002	Feb 09, 2009	Jan	NEWA
	AB		EQ 100MG BASE		N76840	003	Feb 09, 2009	Jan	NEWA
		SUNITINIB MALATE							
		CAPSULE; ORAL							
		SUTENT							
		CPPI CV	EQ 37.5MG BASE		N21938	004	Mar 31, 2009	Mar	NEWA

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

		@	ROXANE	EQ 10MG BASE	N76027	001	Feb 20, 2003	Mar	DISC
		@		EQ 20MG BASE	N76027	002	Feb 20, 2003	Mar	DISC

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION
NEUROLITE

>D>			LANTHEUS MEDCL	N/A/VIAL	N20256	001	Nov 23, 1994	Apr	CPOT
>A>				N/A	N20256	001	Nov 23, 1994	Apr	CPOT

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
DRAXIMAGE MDP-10

>D>	AP	+	DRAXIMAGE	N/A	N18035	001		Apr	CTEC
>A>		+		N/A	N18035	001		Apr	CTEC

>D> DRAXIMAGE MDP-25

>D>	AP	+	DRAXIMAGE	N/A	N18035	002	Feb 27, 2004	Apr	DISC
>A>		@		N/A	N18035	002	Feb 27, 2004	Apr	DISC

>D> TECHNETIUM TC 99M MPI MDP

>D>	AP		GE HEALTHCARE	N/A	N18141	001		Apr	DISC
>A>		@		N/A	N18141	001		Apr	DISC
>A>		@		N/A	N18141	002	Jun 12, 1989	Apr	DISC

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION
TECHNETIUM TC 99M SESTAMIBI

>A>	AP		CARDINAL HEALTH 414	N/A	N78809	001	Apr 28, 2009	Apr	NEWA
>A>	AP		DRAXIMAGE	N/A	N78806	001	Apr 29, 2009	Apr	NEWA

TELBIVUDINE

>A> SOLUTION; ORAL
>A> TYZEKA

>A>		+	NOVARTIS	100MG/5ML	N22154	001	Apr 28, 2009	Apr	NEWA

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

		@	NOVEL LABS INC	30MG	N71457	001	Apr 21, 1987	Mar	CAHN

TEMOZOLOMIDE

POWDER; INTRAVENOUS
TEMODAR

		+	SCHERING	100MG/VIAL	N22277	001	Feb 27, 2009	Feb	NEWA

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
HYTRIN

			ABBOTT	EQ 1MG BASE	N19057	001	Aug 07, 1987	Mar	CTEC
		+		EQ 2MG BASE	N19057	002	Aug 07, 1987	Mar	CTEC
				EQ 5MG BASE	N19057	003	Aug 07, 1987	Mar	CTEC
				EQ 10MG BASE	N19057	004	Aug 07, 1987	Mar	CTEC

TERAZOSIN HYDROCHLORIDE

		@	SANDOZ	EQ 1MG BASE	N74315	001	Dec 31, 1998	Mar	DISC

TABLET; ORAL
TERAZOSIN HYDROCHLORIDE

		@	SANDOZ	EQ 2MG BASE	N74315	002	Dec 31, 1998	Mar	DISC
		@		EQ 5MG BASE	N74315	003	Dec 31, 1998	Mar	DISC
		@		EQ 10MG BASE	N74315	004	Dec 31, 1998	Mar	DISC

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE; SUBCUTANEOUS
FORTEO

			LILLY	0.6MG/2.4ML (0.25MG/ML)	N21318	002	Jun 25, 2008	Feb	NEWA
		+		0.75MG/3ML (0.25MG/ML)	N21318	001	Nov 26, 2002	Feb	CPOT

TESTOSTERONE

GEL; TRANSDERMAL
ANDROGEL

	BX	+	UNIMED PHARMS	1% (5GM/PACKET)	N21015	002	Feb 28, 2000	Mar	CTEC
				1% (2.5GM/PACKET)	N21015	001	Feb 28, 2000	Mar	CTEC

TESTOSTERONE

		@	WATSON LABS	1% (2.5GM/PACKET)	N76737	001	Jan 27, 2006	Mar	DISC
		@		1% (5GM/PACKET)	N76737	002	Jan 27, 2006	Mar	DISC

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTRYL

>A>		@	ENDO PHARM	200MG/ML	N09165	001		Apr	CAHN
>A>	AO	+		200MG/ML	N09165	003		Apr	CAHN
>D>	AO	+	ENDO PHARMS	200MG/ML	N09165	003		Apr	CAHN
>D>		@		200MG/ML	N09165	001		Apr	CAHN
		@		200MG/ML	N09165	001		Mar	CAHN
	AO	+		200MG/ML	N09165	003		Mar	CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL
TYZINE

>D>		+	KENWOOD LABS	0.05%	N86576	002		Apr	CAHN
>D>				0.1%	N86576	001		Apr	CAHN
>A>		+	NYCOMED US	0.05%	N86576	002		Apr	CAHN
>A>				0.1%	N86576	001		Apr	CAHN

SPRAY; NASAL
TYZINE

>D>		+	KENWOOD LABS	0.1%	N86576	003		Apr	CAHN
>A>		+	NYCOMED US	0.1%	N86576	003		Apr	CAHN

THEOPHYLLINE

ELIXIR; ORAL
THEOPHYLLINE

>D>	AA		ACTAVIS MID ATLANTIC	80MG/15ML	N85863	001		Apr	CAHN
>A>	AA		PRECISION DOSE	80MG/15ML	N85863	001		Apr	CAHN

SOLUTION; ORAL
THEOPHYLLINE

		@	ROXANE	80MG/15ML	N87449	001	Sep 15, 1983	Mar	DISC

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOPTIC

	AT	+	ATON	EQ 0.25% BASE	N18086	001		Feb	CAHN

		SOLUTION/DROPS; OPHTHALMIC						
		TIMOPTIC						
AT	+	ATON	EQ 0.5% BASE	N18086	002		Feb	CAHN
		TIMOPTIC IN OCUDOSE						
	+	ATON	EQ 0.25% BASE	N19463	001	Nov 05, 1986	Feb	CAHN
	+		EQ 0.5% BASE	N19463	002	Nov 05, 1986	Feb	CAHN
		SOLUTION, GEL FORMING/DROPS; OPHTHALMIC						
		TIMOPTIC-XE						
AB	+	ATON	EQ 0.25% BASE	N20330	001	Nov 04, 1993	Feb	CAHN
AB	+		EQ 0.5% BASE	N20330	002	Nov 04, 1993	Feb	CAHN
		TABLET; ORAL						
		TIMOLOL MALEATE						
		MYLAN	5MG	N72666	001	Jun 08, 1990	Mar	CTEC
			10MG	N72667	001	Jun 08, 1990	Mar	CTEC
	+		20MG	N72668	001	Jun 08, 1990	Mar	CTEC
		@ SANDOZ	5MG	N72550	001	Apr 13, 1989	Mar	DISC
		@	10MG	N72551	001	Apr 13, 1989	Mar	DISC
		@	20MG	N72552	001	Apr 13, 1989	Mar	DISC
		TOLAZAMIDE						
		TABLET; ORAL						
		TOLAZAMIDE						
		IVAX PHARMS	100MG	N18894	001	Nov 02, 1984	Mar	CTEC
		@ SANDOZ	100MG	N71633	001	Dec 09, 1987	Mar	DISC
		@	250MG	N70289	001	Mar 13, 1986	Mar	DISC
		@	500MG	N70290	001	Mar 13, 1986	Mar	DISC
		TOLBUTAMIDE						
		TABLET; ORAL						
		TOLBUTAMIDE						
		@ SANDOZ	500MG	N86574	001		Mar	DISC
		TOLMETIN SODIUM						
		TABLET; ORAL						
		TOLMETIN SODIUM						
		@ SANDOZ	EQ 200MG BASE	N73588	001	Jul 31, 1992	Mar	DISC
		@	EQ 600MG BASE	N74002	001	Sep 27, 1993	Mar	DISC
		TOPIRAMATE						
		CAPSULE; ORAL						
		TOPAMAX						
AB		ORTHO MCNEIL JANSSEN	15MG	N20844	001	Oct 26, 1998	Mar	CFTG
AB	+		25MG	N20844	002	Oct 26, 1998	Mar	CFTG
		TOPIRAMATE						
AB		BARR	15MG	N76448	001	Apr 15, 2009	Mar	NEWA
AB			25MG	N76448	002	Apr 15, 2009	Mar	NEWA
AB		COBALT LABS INC	15MG	N77868	001	Apr 15, 2009	Mar	NEWA
AB			25MG	N77868	002	Apr 15, 2009	Mar	NEWA
AB		TEVA	15MG	N76575	001	Apr 17, 2009	Mar	NEWA
AB			25MG	N76575	002	Apr 17, 2009	Mar	NEWA
		TABLET; ORAL						
		TOPAMAX						
AB	+	ORTHO MCNEIL JANSSEN	25MG	N20505	004	Dec 24, 1996	Mar	CFTG
AB			50MG	N20505	005	Dec 24, 1996	Mar	CFTG
AB			100MG	N20505	001	Dec 24, 1996	Mar	CFTG
AB			200MG	N20505	002	Dec 24, 1996	Mar	CFTG

TABLET; ORAL

TOPIRAMATE

AB	APOTEX INC	25MG	N77733	001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77733	002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77733	003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77733	004	Mar 27, 2009	Mar	NEWA
AB	AUROBINDO PHARMA	25MG	N78462	001	Mar 27, 2009	Mar	NEWA
AB		50MG	N78462	002	Mar 27, 2009	Mar	NEWA
AB		100MG	N78462	003	Mar 27, 2009	Mar	NEWA
AB		200MG	N78462	004	Mar 27, 2009	Mar	NEWA
AB	BARR	25MG	N76315	001	Mar 27, 2009	Mar	NEWA
AB		100MG	N76315	002	Mar 27, 2009	Mar	NEWA
AB		200MG	N76315	003	Mar 27, 2009	Mar	NEWA
AB	CIPLA LTD	25MG	N76343	001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76343	002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76343	003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76343	004	Mar 27, 2009	Mar	NEWA
AB	COBALT LABS INC	25MG	N77643	001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77643	002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77643	003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77643	004	Mar 27, 2009	Mar	NEWA
AB	GLENMARK GENERICS	25MG	N77627	001	Mar 27, 2009	Mar	NEWA
AB		50MG	N77627	002	Mar 27, 2009	Mar	NEWA
AB		100MG	N77627	003	Mar 27, 2009	Mar	NEWA
AB		200MG	N77627	004	Mar 27, 2009	Mar	NEWA
AB	INVAGEN PHARMS	25MG	N79162	001	Mar 27, 2009	Mar	NEWA
AB		50MG	N79162	002	Mar 27, 2009	Mar	NEWA
AB		100MG	N79162	003	Mar 27, 2009	Mar	NEWA
AB		200MG	N79162	004	Mar 27, 2009	Mar	NEWA
AB	MYLAN	25MG	N76314	001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76314	002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76314	003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76314	004	Mar 27, 2009	Mar	NEWA
AB	PAR PHARM	25MG	N76311	001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76311	002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76311	003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76311	004	Mar 27, 2009	Mar	NEWA
AB	PLIVA HRVATSKA DOO	25MG	N77905	001	Mar 30, 2009	Mar	NEWA
AB		50MG	N77905	002	Mar 30, 2009	Mar	NEWA
AB		100MG	N77905	003	Mar 30, 2009	Mar	NEWA
AB		200MG	N77905	004	Mar 30, 2009	Mar	NEWA
AB	RANBAXY	25MG	N76327	001	Mar 27, 2009	Mar	NEWA
AB		100MG	N76327	002	Mar 27, 2009	Mar	NEWA
AB		200MG	N76327	003	Mar 27, 2009	Mar	NEWA
AB	ROXANE	25MG	N76306	001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76306	002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76306	003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76306	004	Mar 27, 2009	Mar	NEWA
AB	SUN PHARM INDS LTD	25MG	N90278	001	Mar 27, 2009	Mar	NEWA
AB		50MG	N90278	002	Mar 27, 2009	Mar	NEWA
AB		100MG	N90278	003	Mar 27, 2009	Mar	NEWA
AB		200MG	N90278	004	Mar 27, 2009	Mar	NEWA
AB	TEVA	25MG	N76317	001	Mar 27, 2009	Mar	NEWA
AB		50MG	N76317	002	Mar 27, 2009	Mar	NEWA
AB		100MG	N76317	003	Mar 27, 2009	Mar	NEWA
AB		200MG	N76317	004	Mar 27, 2009	Mar	NEWA

TABLET; ORAL
TOPIRAMATE

AB		TORRENT PHARMS	25MG	N79153	001	Mar 27, 2009	Mar	NEWA
AB			50MG	N79153	002	Mar 27, 2009	Mar	NEWA
AB			100MG	N79153	003	Mar 27, 2009	Mar	NEWA
AB			200MG	N79153	004	Mar 27, 2009	Mar	NEWA
AB		UNICHEM	25MG	N90162	001	Mar 27, 2009	Mar	NEWA
AB			50MG	N90162	002	Mar 27, 2009	Mar	NEWA
AB			100MG	N90162	003	Mar 27, 2009	Mar	NEWA
AB		ZYDUS PHARMS USA INC	25MG	N78235	001	Mar 27, 2009	Mar	NEWA
AB			50MG	N78235	002	Mar 27, 2009	Mar	NEWA
AB			100MG	N78235	003	Mar 27, 2009	Mar	NEWA
AB			200MG	N78235	004	Mar 27, 2009	Mar	NEWA

TORSEMIDE

TABLET; ORAL
TORSEMIDE

AB		HETERO DRUGS	5MG	N79234	001	Jan 27, 2009	Jan	NEWA
AB			10MG	N79234	002	Jan 27, 2009	Jan	NEWA
AB			20MG	N79234	003	Jan 27, 2009	Jan	NEWA
AB			100MG	N79234	004	Jan 27, 2009	Jan	NEWA

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
RYZOLT

BC	+	PURDUE PHARMA	100MG	N21745	001	Dec 30, 2008	Mar	CAHN
BC			200MG	N21745	002	Dec 30, 2008	Mar	CAHN
BC			300MG	N21745	003	Dec 30, 2008	Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
TRAMADOL HYDROCHLORIDE

		@ ETHYPHARM NORTH	50MG	N21693	001	May 05, 2005	Mar	CAHN

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HYDROCHLORIDE

AB		ALVOGEN	50MG	N71636	001	Apr 18, 1988	Feb	CAHN
AB			100MG	N71514	001	Apr 18, 1988	Feb	CAHN
		@ SANDOZ	50MG	N72484	001	Apr 30, 1990	Mar	DISC
		@	100MG	N72483	001	Apr 30, 1990	Mar	DISC

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
SANCTURA XR

>A>	+	ALLERGAN	60MG	N22103	001	Aug 03, 2007	Apr	CAHN
>D>	+	ENDO PHARMS	60MG	N22103	001	Aug 03, 2007	Apr	CAHN
	+		60MG	N22103	001	Aug 03, 2007	Mar	CAHN

TABLET; ORAL
SANCTURA

>A>	+	ALLERGAN	20MG	N21595	001	May 28, 2004	Apr	CAHN
>D>	+	ENDO PHARMS	20MG	N21595	001	May 28, 2004	Apr	CAHN
	+		20MG	N21595	001	May 28, 2004	Mar	CAHN

TRYPAN BLUE

SOLUTION; OPHTHALMIC
MEMBRANEBLUE

	+	DORC	0.15%	N22278	001	Feb 20, 2009	Feb	NEWA

VALRUBICIN

SOLUTION; INTRAVESICAL

VALSTAR PRESERVATIVE FREE

>A>		+	ENDO PHARM	40MG/ML	N20892	001	Sep 25, 1998	Apr	CAHN
>D>		+	ENDO PHARMS	40MG/ML	N20892	001	Sep 25, 1998	Apr	CAHN
		+		40MG/ML	N20892	001	Sep 25, 1998	Mar	CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

>D>		+	ABRAXIS PHARM	EQ 10GM BASE/VIAL	N62663	004	Nov 28, 1997	Apr	CTEC
>A>	AP	+		EQ 10GM BASE/VIAL	N62663	004	Nov 28, 1997	Apr	CTEC
>A>	AP		HOSPIRA INC	EQ 10GM BASE/VIAL	N65455	001	Apr 29, 2009	Apr	NEWA

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

>D>	AP		BEDFORD	2.5MG/ML	N72888	001	Jul 28, 1995	Apr	DISC
>A>		@		2.5MG/ML	N72888	001	Jul 28, 1995	Apr	DISC

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

		@	SANDOZ	40MG	N73168	001	Jul 31, 1992	Mar	DISC
		@		80MG	N71423	001	May 24, 1988	Mar	DISC
		@		120MG	N71424	001	May 25, 1988	Mar	DISC

ZOLPIDEM TARTRATE

TABLET; SUBLINGUAL

EDLUAR

			OREXO AB	5MG	N21997	001	Mar 13, 2009	Mar	NEWA
		+		10MG	N21997	002	Mar 13, 2009	Mar	NEWA

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

	OHM LABS	650MG	N76200	001	Mar 19, 2002	Mar	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	DR REDDYS LABS LTD	5MG/5ML	N90474	002	Mar 30, 2009	Mar	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	DR REDDYS LABS LTD	5MG/5ML	N90474	001	Mar 30, 2009	Mar	NEWA

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	ORCHID HLTHCARE	5MG	N78862	001	Feb 19, 2009	Feb	NEWA
		10MG	N78862	002	Feb 19, 2009	Feb	NEWA

CETIRIZINE HYDROCHLORIDE HIVES

	ORCHID HLTHCARE	5MG	N78862	003	Feb 19, 2009	Feb	NEWA
		10MG	N78862	004	Feb 19, 2009	Feb	NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

>A>	AVANTHI INC	12MG	N40829	001	May 13, 2009	Apr	NEWA

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DELSYM

+	RECKITT BENCKISER	EQ 30MG HBR/5ML	N18658	001	Oct 08, 1982	Feb	CAHN

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

	BANNER PHARMACAPS	EQ 200MG FREE ACID AND POTASSIUM SALT	N78682	001	Mar 24, 2009	Mar	NEWA

MIDOL LIQUID GELS

+	BANNER PHARMACAPS	200MG	N21472	001	Oct 18, 2002	Feb	CTNA

TABLET; ORAL

IBUPROFEN

	@ SANDOZ	200MG	N70733	001	Sep 19, 1986	Mar	DISC
>D>	MEDIPREN						
>D>	MCNEIL	200MG	N70475	001	Feb 06, 1986	Apr	DISC
>A>	@	200MG	N70475	001	Feb 06, 1986	Apr	DISC
>D>		200MG	N71215	001	Jun 26, 1986	Apr	DISC
>A>	@	200MG	N71215	001	Jun 26, 1986	Apr	DISC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

HUMULIN 50/50

	@ LILLY	50 UNITS/ML;50 UNITS/ML	N20100	001	Apr 29, 1992	Jan	DISC

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

	IVAX PHARMS	EQ 2MG BASE	N76880	001	Feb 18, 2009	Feb	NEWA
		EQ 4MG BASE	N77850	001	Feb 18, 2009	Feb	NEWA

POTASSIUM IODIDE

SOLUTION; ORAL

THYROSHIELD

>D>	FLEMING	65MG/ML	N77218	001	Jan 12, 2005	Apr	CRLD
>A>	+	65MG/ML	N77218	001	Jan 12, 2005	Apr	CRLD

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

	@ SANDOZ	EQ 75MG BASE	N75519	001	Sep 26, 2002	Mar	DISC

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2009

NO APRIL 2009 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO APRIL 2009 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ADAPALENE; BENZOYL PEROXIDE - EPIDUO						
022320 001	4717720	May 31, 2010	DS DP			
	RE34440	May 31, 2010	U-818			
ALBUTEROL SULFATE - VENTOLIN HFA						
020983 001	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 06, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
ALPRAZOLAM - ALPRAZOLAM						
078088 001					**>A>** PC	Jul 13, 2009
ALPRAZOLAM - ALPRAZOLAM						
078088 002					**>A>** PC	Jul 13, 2009
ALPRAZOLAM - ALPRAZOLAM						
078088 003					**>A>** PC	Jul 13, 2009
ALPRAZOLAM - ALPRAZOLAM						
078088 004					**>A>** PC	Jul 13, 2009
AMIODARONE HYDROCHLORIDE - NEXTERONE						
022325 001	5134127	Jan 23, 2010	DP			
	5376645	Jan 23, 2010	DP			
	6869939	May 04, 2022	DP			
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 001	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 002	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 003	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 004	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 005	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 006	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 007	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 008	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 009	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 010	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET						
021540 011	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
022314 001	**>A>** 5399578	Mar 21, 2012	DS DP U-3		**>A>** NC	Apr 30, 2012
	>A> 5399578*PED	Sep 21, 2012				
	>A> 6294197	Jun 18, 2017	DP U-3			
	>A> 6294197*PED	Dec 18, 2017				
AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
022314 002	**>A>** 5399578	Mar 21, 2012	DS DP U-3		**>A>** NC	Apr 30, 2012
	>A> 5399578*PED	Sep 21, 2012				
	>A> 6294197	Jun 18, 2017	DP U-3			
	>A> 6294197*PED	Dec 18, 2017				
AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
022314 003	**>A>** 5399578	Mar 21, 2012	DS DP U-3		**>A>** NC	Apr 30, 2012
	>A> 5399578*PED	Sep 21, 2012				
	>A> 6294197	Jun 18, 2017	DP U-3			
	>A> 6294197*PED	Dec 18, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
022314 004	**>A>** 5399578	Mar 21, 2012	DS DP U-3		**>A>** NC	Apr 30, 2012
	>A> 5399578*PED	Sep 21, 2012				
	>A> 6294197	Jun 18, 2017	DP U-3			
	>A> 6294197*PED	Dec 18, 2017				
AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT						
022314 005	**>A>** 5399578	Mar 21, 2012	DS DP U-3		**>A>** NC	Apr 30, 2012
	>A> 5399578*PED	Sep 21, 2012				
	>A> 6294197	Jun 18, 2017	DP U-3			
	>A> 6294197*PED	Dec 18, 2017				
AMMONIA, N-13 - AMMONIA N 13						
022119 001					**>A>** NCE	Aug 23, 2012
					>A> W	Aug 23, 2012
AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE - PREVPAC						
050757 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5013743	Feb 12, 2010	U-452			
	5013743*PED	Aug 12, 2010				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
ANASTROZOLE - ARIMIDEX						
020541 001	RE36617	Dec 27, 2009	DS DP U-946			
ARMODAFINIL - NUVIGIL						
021875 002					NP	Jun 15, 2010
ARMODAFINIL - NUVIGIL						
021875 005					NP	Jun 15, 2010
ARTEMETHER; LUMEFANTRINE - COARTEM						
022268 001					**>A>** NCE	Apr 07, 2014
ATORVASTATIN CALCIUM - LIPITOR						
020702 001	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
ATORVASTATIN CALCIUM - LIPITOR						
020702 002	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
ATORVASTATIN CALCIUM - LIPITOR						
020702 003	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				
ATORVASTATIN CALCIUM - LIPITOR						
020702 004	RE40667	Dec 28, 2010	DS DP U-162			
	RE40667*PED	Jun 28, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZITHROMYCIN - AZASITE						
050810 001	5192535	Mar 09, 2010	DP U-709			
	6239113	Mar 31, 2019	U-709			
	6569443	Mar 31, 2019	DP U-709			
	6861411	Nov 25, 2018	U-709			
	7056893	Mar 31, 2019	DP U-709			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA						
050819 001	5733886	Mar 31, 2015	DP U-124			
	6117843	Feb 18, 2012	DP			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - DUAC						
050741 001	5466446	Feb 16, 2014	DS DP			
BENZYL ALCOHOL - BENZYL ALCOHOL						
022129 001					>A> NCE	Apr 09, 2014
BETAMETHASONE VALERATE - LUXIQ						
020934 001	7078058	May 24, 2017	DP			
BIMATOPROST - LATISSE						
022369 001					NP	Dec 24, 2011
BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA						
050786 001	5196205	Mar 23, 2010	U-933			
	5476669	Mar 23, 2010	U-933			
	6350468	Dec 14, 2018	U-956			
	6350468	Dec 14, 2018	U-932			
BUDESONIDE - PULMICORT RESPULES						
020929 001	>A> 7524834	Nov 11, 2018	DP U-966			
	>A> 7524834*PED	May 11, 2019				
BUDESONIDE - PULMICORT RESPULES						
020929 002	>A> 7524834	Nov 11, 2018	DP U-966			
	>A> 7524834*PED	May 11, 2019				
BUDESONIDE - PULMICORT RESPULES						
020929 003	>A> 7524834	Nov 11, 2018	DP U-966			
	>A> 7524834*PED	May 11, 2019				
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
021929 001					I-582	Feb 27, 2012
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT						
021929 002					I-582	Feb 27, 2012
CALCITRIOL - VECTICAL						
022087 001					NDF	Jan 23, 2012
CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE						
020958 001	5075114	May 23, 2010	DP			
	5075114*PED	Nov 23, 2010				
	6814978	Aug 26, 2021	DP			
	6814978*PED	Feb 26, 2022				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)						
021823 001	**>A>** 5583122	Dec 10, 2013	DS DP U-353			
	>A> 5583122*PED	Jun 10, 2014				
	>A> 5994329	Jul 17, 2018	U-353			
	>A> 5994329*PED	Jan 17, 2019				
	>A> 6015801	Jul 17, 2018	U-353			
	>A> 6015801*PED	Jan 17, 2019				
	>A> 6096342	Nov 21, 2011	DP			
	>A> 6096342*PED	May 21, 2012				
	>A> 6165513	Jun 10, 2018	DP			
	>A> 6165513*PED	Dec 10, 2018				
	>A> 6432932	Jul 17, 2018	U-595			
	>A> 6432932*PED	Jan 17, 2019				
	>A> 6465443	Aug 14, 2018	DP			
	>A> 6465443*PED	Feb 14, 2019				
CICLESONIDE - ALVESCO						
021658 002					NDF	Jan 10, 2011
					NCE	Oct 20, 2011
CICLESONIDE - ALVESCO						
021658 003					NDF	Jan 10, 2011
					NCE	Oct 20, 2011
CLARITHROMYCIN - BIAXIN XL						
050775 001	6551616	Jul 15, 2017	U-924			
CLOBETASOL PROPIONATE - OLUX						
021142 001	6126920	Mar 01, 2016	U-484			
CLOPIDOGREL BISULFATE - PLAVIX						
020839 002	4847265	Nov 17, 2011	DS DP			
	6429210	Jun 10, 2019	DS DP			
	6504030	Jun 10, 2019	DS			
COLESEVELAM HYDROCHLORIDE - WELCHOL						
021141 001	5607669	Jun 10, 2014	U-323			
	5607669*PED	Dec 10, 2014				
	5679717	Apr 29, 2014	U-323			
	5679717*PED	Oct 29, 2014				
	5693675	Dec 02, 2014				
	5693675*PED	Jun 02, 2015				
	5917007	Apr 29, 2014	U-323			
	5917007*PED	Oct 29, 2014				
	5919832	Jun 10, 2014				
	5919832*PED	Dec 10, 2014				
	6066678	Jun 10, 2014	U-323			
	6066678*PED	Dec 10, 2014				
	6433026	Jun 10, 2014				
	6433026*PED	Dec 10, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COLESEVELAM HYDROCHLORIDE - WELCHOL							
021176 001		5607669	Jun 10, 2014	U-323		I-553	Jan 18, 2011
		5607669*PED	Dec 10, 2014			PED	Jul 18, 2011
		5679717	Apr 29, 2014	U-323			
		5679717*PED	Oct 29, 2014				
		5693675	Dec 02, 2014	DS			
		5693675*PED	Jun 02, 2015				
		5917007	Apr 29, 2014	DS U-323			
		5917007*PED	Oct 29, 2014				
		5919832	Apr 29, 2014	DS			
		5919832*PED	Oct 29, 2014				
		6066678	Apr 29, 2014	DS U-323			
		6066678*PED	Oct 29, 2014				
		6433026	Apr 29, 2014	DS			
		6433026*PED	Oct 29, 2014				
		6784254	Apr 29, 2014	DS DP			
		6784254*PED	Oct 29, 2014				
		7101960	Apr 29, 2014	DS DP U-757			
		7101960*PED	Oct 29, 2014				
		7229613	Apr 17, 2022	U-851			
		7229613*PED	Oct 17, 2022				
CYCLOSPORINE - SANDIMMUNE							
050625 001	**>A>**	7511014	Feb 16, 2010	DP			
CYCLOSPORINE - SANDIMMUNE							
050625 002	**>A>**	7511014	Feb 16, 2010	DP			
CYCLOSPORINE - SANDIMMUNE							
050625 003	**>A>**	7511014	Feb 16, 2010	DP			
DASATINIB - SPRYCEL							
021986 001	**>A>**	7491725	Oct 13, 2025	DS DP			
DASATINIB - SPRYCEL							
021986 002	**>A>**	7491725	Oct 13, 2025	DS DP			
DASATINIB - SPRYCEL							
021986 003	**>A>**	7491725	Oct 13, 2025	DS DP			
DASATINIB - SPRYCEL							
021986 004	**>A>**	7491725	Oct 13, 2025	DS DP			
DEGARELIX ACETATE - DEGARELIX ACETATE							
022201 001		5925730	Apr 11, 2017	DS DP U-943			
DEGARELIX ACETATE - DEGARELIX ACETATE							
022201 002		5925730	Apr 11, 2017	DS DP U-943			
DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST							
050818 001		5149694	Sep 22, 2009	U-953			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXLANSOPRAZOLE - KAPIDEX						
022287 001	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
DEXLANSOPRAZOLE - KAPIDEX						
022287 002	5045321	Sep 03, 2008	DP		NP	Jan 30, 2012
	5045321*PED	Mar 03, 2009			PED	Jul 30, 2012
	5093132	Sep 03, 2008	DP U-949			
	5093132	Sep 03, 2008	DP U-950			
	5093132	Sep 03, 2008	DP U-951			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP U-949			
	5433959	Sep 03, 2008	DP U-950			
	5433959	Sep 03, 2008	DP U-951			
	5433959*PED	Mar 03, 2009				
	6462058	Jun 15, 2020	DS DP U-951			
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-949			
	6462058*PED	Dec 15, 2020				
	6664276	Jun 15, 2020	DS DP U-949			
	6664276	Jun 15, 2020	DS DP U-950			
	6664276	Jun 15, 2020	DS DP U-951			
	6664276*PED	Dec 15, 2020				
	6939971	Jun 15, 2020	U-949			
	6939971	Jun 15, 2020	U-950			
	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DILTIAZEM HYDROCHLORIDE - CARDIZEM CD							
020062 005		5286497	May 20, 2011	DP			
		5439689	Aug 08, 2012	DP U-107			
		5470584	May 20, 2011	DP			
DINOPROSTONE - CERVIDIL							
020411 001	**>A>**	5269321	Jul 14, 2012	DP U-110			
DIVALPROEX SODIUM - DIVALPROEX SODIUM							
077567 002						PC	Aug 01, 2009
DOXERCALCIFEROL - HECTOROL							
021027 001		5707980	Aug 17, 2010	U-321	Y		
ELTROMBOPAG OLAMINE - PROMACTA							
022291 001		7473686	Jul 24, 2021	DS DP U-930			
ELTROMBOPAG OLAMINE - PROMACTA							
022291 002		7473686	Jul 24, 2021	DS DP U-930			
ESCITALOPRAM OXALATE - LEXAPRO							
021323 001						NPP	Mar 19, 2012
ESCITALOPRAM OXALATE - LEXAPRO							
021323 002						NPP	Mar 19, 2012
ESCITALOPRAM OXALATE - LEXAPRO							
021323 003						NPP	Mar 19, 2012
ESCITALOPRAM OXALATE - LEXAPRO							
021365 001						NPP	Mar 19, 2012
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
021153 001						**>A>** NPP	Apr 28, 2009
						>A> PED	Oct 28, 2009
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
021153 002						**>A>** NPP	Apr 28, 2009
						>A> PED	Oct 28, 2009
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
021957 001						**>A>** NPP	Apr 28, 2009
						>A> PED	Oct 28, 2009
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
021957 002						**>A>** NPP	Apr 28, 2009
						>A> PED	Oct 28, 2009
ESOMEPRAZOLE MAGNESIUM - NEXIUM							
022101 001						**>A>** NPP	Feb 27, 2011
						>A> PED	Aug 27, 2011
ESTRADIOL - ELESTRIN							
021813 001		7470433	Aug 03, 2021	DP			
EVEROLIMUS - AFINITOR							
022334 001		5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
		6004973	Jul 12, 2016	DP			
		7297703	Dec 06, 2019	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EVEROLIMUS - AFINITOR						
022334 002	5665772	Sep 09, 2014	DS DP		NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP			
	7297703	Dec 06, 2019	DP			
FEBUXOSTAT - ULORIC						
021856 001	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
FEBUXOSTAT - ULORIC						
021856 002	5614520	Mar 25, 2014	DS DP U-954		NCE	Feb 13, 2014
	6225474	Jun 18, 2019	DS			
	7361676	Mar 08, 2024	DP			
FLUDARABINE PHOSPHATE - FLUDARABINE PHOSPHATE						
022273 001	7148207	Dec 20, 2022	DP U-944		NDF	Dec 18, 2011
FLUOXETINE HYDROCHLORIDE - PROZAC						
018936 001	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE - PROZAC						
018936 003	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE - PROZAC						
018936 006	6960577	Nov 01, 2017	U-963		I-589	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
021520 001	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
021520 002	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
021520 003	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
021520 004	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX						
021520 005	6960577	Nov 01, 2017	U-962		I-593	Mar 19, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - FLOVENT DISKUS 100						
020833 002	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
FLUTICASONE PROPIONATE - FLOVENT DISKUS 250						
020833 003	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - FLOVENT DISKUS 50						
020833 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - FLOVENT HFA						
021433 001	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Jun 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - FLOVENT HFA						
021433 002	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015				
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015				
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021				
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE - FLOVENT HFA						
021433 003	5658549	Aug 19, 2014	DP U-710			
	5658549*PED	Feb 19, 2015	U-710			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-582			
	6253762*PED	Oct 14, 2015	U-582			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6431168	Jun 08, 2018	DP			
	6431168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP U-583			
	6546928*PED	Oct 14, 2015	U-583			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-581			
	6743413*PED	Dec 01, 2021	U-581			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2019				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50						
021077 001	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50						
021077 002	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50						
021077 003	5590645	Mar 01, 2011	DP		M-84	Mar 31, 2012
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
021254 001	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015				
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013				
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018				
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017				
	6510969*PED	Jun 23, 2018				
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015				
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
021254 002	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA						
021254 003	5658549	Aug 19, 2014	DP U-738			
	5658549*PED	Feb 19, 2015	DP U-738			
	5674472	Oct 07, 2014	DP			
	5674472*PED	Apr 07, 2015	DP			
	6161724	Jan 16, 2018	DP			
	6161724*PED	Jul 16, 2018				
	6170717	Dec 23, 2017	DP			
	6170717*PED	Jun 23, 2018				
	6251368	Dec 04, 2012	DP			
	6251368*PED	Jun 04, 2013	DP			
	6253762	Apr 14, 2015	DP U-738			
	6253762*PED	Oct 14, 2015	DP U-738			
	6315173	Dec 23, 2017	DP			
	6315173*PED	Jun 23, 2018	DP			
	6341168	Jun 08, 2018	DP			
	6341168*PED	Dec 08, 2018				
	6435372	Jan 16, 2018	DP			
	6435372*PED	Jul 16, 2018				
	6510969	Dec 23, 2017	DP			
	6510969*PED	Jun 23, 2018	DP			
	6546928	Apr 14, 2015	DP			
	6546928*PED	Oct 14, 2015	DP			
	6596260	Aug 10, 2014	DP			
	6596260*PED	Feb 10, 2015				
	6743413	Jun 01, 2021	U-841			
	6743413*PED	Dec 01, 2021	U-841			
	6938796	Jan 16, 2018	DP			
	6938796*PED	Jul 16, 2018				
	6966467	Dec 23, 2017	DP			
	6966467*PED	Jun 23, 2018				
	6997349	Jan 16, 2018	DP			
	6997349*PED	Jul 16, 2018				
	7107986	Jun 08, 2018	DP			
	7107986*PED	Dec 08, 2018				
	7143908	Jan 16, 2018	DP			
	7143908*PED	Jul 16, 2018				
	7350676	Aug 24, 2018	DP			
	7350676*PED	Feb 24, 2019				
	7500444	Jan 04, 2025	DP			
	7500444*PED	Jul 04, 2025				
FLUVOXAMINE MALEATE - LUVOX						
021519 001					M-83	Apr 14, 2011
FLUVOXAMINE MALEATE - LUVOX						
021519 002					M-83	Apr 14, 2011
FLUVOXAMINE MALEATE - LUVOX						
021519 003					M-83	Apr 14, 2011
FOSPROPOFOL DISODIUM - LUSEDRA						
022244 001	6204257	Jun 07, 2018	DS DP U-945		NCE	Dec 12, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GADODIAMIDE - OMNISCAN						
022066 002	5362475	Nov 08, 2011	DS			
GLATIRAMER ACETATE - COPAXONE						
020622 001					I-594	Feb 27, 2012
GLATIRAMER ACETATE - COPAXONE						
020622 002					I-594	Feb 27, 2012
GOSERELIN ACETATE - ZOLADEX						
019726 001	7500964	Feb 26, 2021	DP			
GOSERELIN ACETATE - ZOLADEX						
020578 001	7500964	Feb 26, 2021	DP			
HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT						
021162 003	5591762	Jan 07, 2014	DS DP U-3			
IMATINIB MESYLATE - GLEEVEC						
021588 001					I-583	Dec 19, 2011
IMATINIB MESYLATE - GLEEVEC						
021588 002					I-583	Dec 19, 2011
INSULIN DETEMIR RECOMBINANT - LEVEMIR						
021536 001	5750497	May 16, 2019	DS DP U-668			
INSULIN GLARGINE RECOMBINANT - LANTUS						
021081 001	5656722	Aug 12, 2014	DS DP U-948			
	5656722*PED	Feb 12, 2015				
	7476652	Jul 23, 2023	DP			
	7476652*PED	Jan 23, 2024				
INSULIN GLULISINE RECOMBINANT - APIDRA						
021629 002					NCE	Apr 16, 2009
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR						
021629 003					NPP	Oct 24, 2011
					NCE	Apr 16, 2009
IODIXANOL - VISIPAQUE 270						
020351 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
IODIXANOL - VISIPAQUE 270						
020808 001	5366722	Nov 22, 2011	DP			
	RE36418	Jul 12, 2011	DP			
IODIXANOL - VISIPAQUE 320						
020351 002	RE36418	Jul 12, 2011	DP			
IODIXANOL - VISIPAQUE 320						
020808 002	RE36418	Jul 12, 2011	DP			
IXABEPILONE - IXEMPRA KIT						
022065 001	6605599	May 26, 2018	DS DP U-961			
	6670384	Jan 23, 2022	DP U-960			
	6670384	Jan 23, 2022	DP U-959			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
>A>	7312237	Aug 21, 2024	U-965			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IXABEPILONE - IXEMPRA KIT						
022065 002	6605599	May 26, 2018	DS DP U-961			
	6670384	Jan 23, 2022	DP U-960			
	6670384	Jan 23, 2022	DP U-959			
	7022330	Jan 23, 2022	DP U-958			
	7125899	May 26, 2018	DS DP U-957			
	>A> 7312237	Aug 21, 2024	U-965			
LANSOPRAZOLE - PREVACID						
020406 001					**>A>** M-85	Oct 28, 2011
					>A> PED	Apr 28, 2012
LANSOPRAZOLE - PREVACID						
020406 002					**>A>** M-85	Oct 28, 2011
					>A> PED	Apr 28, 2012
LANSOPRAZOLE - PREVACID						
021281 001					**>A>** M-85	Oct 28, 2011
					>A> PED	Apr 28, 2012
LANSOPRAZOLE - PREVACID						
021281 002					**>A>** M-85	Oct 28, 2011
					>A> PED	Apr 28, 2012
LANSOPRAZOLE - PREVACID						
021428 001	7431942	May 17, 2019	DP		**>A>** M-85	Oct 28, 2011
	7431942*PED	Nov 17, 2019			**>A>** PED	Apr 28, 2012
LANSOPRAZOLE - PREVACID						
021428 002	7431942	May 17, 2019	DP		**>A>** M-85	Oct 28, 2011
	7431942*PED	Nov 17, 2019			**>A>** PED	Apr 28, 2012
LANSOPRAZOLE - PREVACID IV						
021566 001	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	7396841	Aug 17, 2021	DP U-947			
	7396841*PED	Feb 17, 2022				
LANSOPRAZOLE; NAPROXEN - PREVACID NAPRAPAC 500 (COPACKAGED)						
021507 004	4628098	May 10, 2009	DS			
	4628098*PED	Nov 10, 2009				
	5045321	Sep 03, 2008	DP			
	5045321*PED	Mar 03, 2009				
	5093132	Sep 03, 2008	DP			
	5093132*PED	Mar 03, 2009				
	5433959	Sep 03, 2008	DP			
	5433959*PED	Mar 03, 2009				
LANTHANUM CARBONATE - FOSRENOL						
021468 001	5968976	Oct 26, 2018	DP U-613			
LANTHANUM CARBONATE - FOSRENOL						
021468 002	5968976	Oct 26, 2018	DP U-613			
LANTHANUM CARBONATE - FOSRENOL						
021468 003	5968976	Oct 26, 2018	DP U-613			
LANTHANUM CARBONATE - FOSRENOL						
021468 004	5968976	Oct 26, 2018	DP U-613			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVETIRACETAM - KEPPRA XR						
022285 002					NDF	Sep 12, 2011
LIDOCAINE HYDROCHLORIDE - ZINGO						
022114 001					NPP	Jan 08, 2012
MEMANTINE HYDROCHLORIDE - NAMENDA						
021487 001	5061703	Apr 11, 2015	U-539			
MEMANTINE HYDROCHLORIDE - NAMENDA						
021487 002	5061703	Apr 11, 2015	U-539			
MEMANTINE HYDROCHLORIDE - NAMENDA						
021627 001	5061703	Apr 11, 2015	U-539			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
022256 001	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
022256 002	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
022256 003	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
022256 004	6602911	Nov 05, 2021	U-882		NCE	Jan 14, 2014
	>A> 6992110	Nov 05, 2021	U-882			
MOMETASONE FUROATE - ASMANEX TWISTHALER						
021067 002	5394868	Jun 25, 2012	DP		NPP	Feb 01, 2011
	5394868*PED	Dec 25, 2012				
	5687710	Nov 18, 2014	DP			
	5687710*PED	May 18, 2015				
	5829434	Nov 03, 2015	DP			
	5829434*PED	May 03, 2016				
	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6240918	Feb 20, 2017	DP			
	6240918*PED	Aug 20, 2017				
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
	6503537	Mar 17, 2018	DP			
	6503537*PED	Sep 17, 2018				
	6677322	Jan 27, 2014	U-645			
	6677322*PED	Jul 27, 2014				
	6949532	Jan 27, 2014	U-645			
	6949532*PED	Jul 27, 2014				
MORPHINE SULFATE - AVINZA						
021260 005	6066339	Nov 25, 2017	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE - AVINZA						
021260 006	6066339	Nov 25, 2017	DP			
NITROGLYCERIN - NITROMIST						
021780 001	5869082	Apr 16, 2016	DP			
OLANZAPINE - ZYPREXA						
020592 001	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA						
020592 002	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA						
020592 003	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA						
020592 004	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA						
020592 005	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA						
020592 006	6960577	Nov 01, 2017	U-963		I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA ZYDIS						
021086 001	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA ZYDIS						
021086 002	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA ZYDIS						
021086 003	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
OLANZAPINE - ZYPREXA ZYDIS						
021086 004	6960577	Nov 01, 2017	U-964		I-591	Mar 19, 2012
OMEGA-3-ACID ETHYL ESTERS - LOVAZA						
021654 001	5656667	Apr 10, 2017	DS DP U-822			
OXYBUTYNIN CHLORIDE - GELNIQUE						
022204 001	7029694	Apr 26, 2020	DP U-318		NDF	Jan 27, 2012
	7179483	Apr 26, 2020	U-318			
PALIPERIDONE - INVEGA						
021999 006	5158952	Oct 27, 2009	DP U-90			
PANTOPRAZOLE SODIUM - PROTONIX						
020987 001	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				
PANTOPRAZOLE SODIUM - PROTONIX						
020987 002	4758579	Jul 19, 2010				
	4758579*PED	Jan 19, 2011				
	5997903	Dec 07, 2016				
	5997903*PED	Jun 07, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANTOPRAZOLE SODIUM - PROTONIX							
022020 001		4758579	Jul 19, 2010	DS DP U-859			
		4758579*PED	Jan 19, 2011				
PANTOPRAZOLE SODIUM - PROTONIX IV							
020988 001		4758579	Jul 19, 2010				
		4758579*PED	Jan 19, 2011				
		6780881	Nov 17, 2021	DP			
		6780881*PED	May 17, 2022				
		7351723	Nov 17, 2021	DP			
		7351723*PED	May 17, 2022				
PHENTOLAMINE MESYLATE - ORAVERSE							
022159 001	**>A>**	6764678	May 11, 2021	U-967			
	>A>	6872390	May 11, 2021	DP			
	>A>	7229630	Jun 20, 2023	DP			
PRAMLINTIDE ACETATE - SYMLIN							
021332 002		5814600	Sep 29, 2015	U-639			
		5814600	Sep 29, 2015	U-638			
		5814600	Sep 29, 2015	U-637			
		5998367	Mar 08, 2011	DS DP			
		6114304	Sep 05, 2017	U-640			
		6114304	Sep 05, 2017	U-637			
		6608029	Sep 07, 2013	U-641			
		6608029	Sep 07, 2013	U-640			
		6608029	Sep 07, 2013	U-637			
		6610824	Mar 03, 2011	DS			
		7407934	Mar 08, 2011	U-640			
		7407934	Mar 08, 2011	U-637			
PRAMLINTIDE ACETATE - SYMLIN							
021332 003		5814600	Sep 29, 2015	U-639			
		5814600	Sep 29, 2015	U-638			
		5814600	Sep 29, 2015	U-637			
		5998367	Mar 08, 2011	DS DP			
		6114304	Sep 05, 2017	U-640			
		6114304	Sep 05, 2017	U-637			
		6608029	Sep 07, 2013	U-641			
		6608029	Sep 07, 2013	U-640			
		6608029	Sep 07, 2013	U-637			
		6610824	Mar 03, 2011	DS			
		7407934	Mar 08, 2011	U-640			
		7407934	Mar 08, 2011	U-637			
QUETIAPINE FUMARATE - SEROQUEL							
020639 001		4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
						I-503	Oct 20, 2009
		4879288*PED	Mar 26, 2012			PED	Nov 13, 2011
						PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL							
020639 002		4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
						I-503	Oct 20, 2009
		4879288*PED	Mar 26, 2012			PED	Nov 13, 2011
						PED	Apr 20, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
QUETIAPINE FUMARATE - SEROQUEL						
020639 003	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL						
020639 004	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL						
020639 005	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL						
020639 006	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL						
020639 007	4879288	Sep 26, 2011	DS DP U-550		I-560	May 13, 2011
	4879288*PED	Mar 26, 2012			I-503	Oct 20, 2009
					PED	Nov 13, 2011
					PED	Apr 20, 2010
QUETIAPINE FUMARATE - SEROQUEL XR						
022047 001	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
QUETIAPINE FUMARATE - SEROQUEL XR						
022047 002	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
QUETIAPINE FUMARATE - SEROQUEL XR						
022047 003	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
QUETIAPINE FUMARATE - SEROQUEL XR						
022047 004	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
QUETIAPINE FUMARATE - SEROQUEL XR						
022047 005	4879288	Sep 26, 2011	DS DP U-814		D-117	Oct 08, 2011
	4879288	Sep 26, 2011	DS DP U-601		I-576	Oct 08, 2011
	4879288*PED	Mar 26, 2012			I-575	Oct 08, 2011
	5948437	May 28, 2017	DP U-814		I-574	Oct 08, 2011
	5948437	May 28, 2017	DP U-601		NDF	May 17, 2010
	5948437*PED	Nov 28, 2017			PED	Apr 08, 2012
					PED	Nov 17, 2010
REMIFENTANIL HYDROCHLORIDE - ULTIVA						
020630 001	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
REMIFENTANIL HYDROCHLORIDE - ULTIVA						
020630 002	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
REMIFENTANIL HYDROCHLORIDE - ULTIVA						
020630 003	5019583	Jul 12, 2010	DS DP U-952			
	5019583*PED	Jan 12, 2011				
REPAGLINIDE - PRANDIN						
020741 001	**>A>** 6677358	Jun 12, 2018	DS DP U-968			
REPAGLINIDE - PRANDIN						
020741 002	**>A>** 6677358	Jun 12, 2018	DS DP U-968			
REPAGLINIDE - PRANDIN						
020741 003	**>A>** 6677358	Jun 12, 2018	DS DP U-968			
RISEDRONATE SODIUM - ACTONEL						
020835 001	**>A>** 5583122	Dec 10, 2013	U-222			
	>A> 5583122*PED	Jun 10, 2014				
	>A> 6096342	Nov 22, 2011				
	>A> 6096342*PED	May 22, 2012				
	>A> 6165513	Jun 10, 2018				
	>A> 6165513*PED	Dec 10, 2018				
RISEDRONATE SODIUM - ACTONEL						
020835 002	**>A>** 5583122	Dec 10, 2013	U-222			
	>A> 5583122*PED	Jun 10, 2014				
	>A> 6096342	Nov 22, 2011				
	>A> 6096342*PED	May 22, 2012				
	>A> 6165513	Jun 10, 2018				
	>A> 6165513*PED	Dec 10, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RISEDRONATE SODIUM - ACTONEL						
020835 003	**>A>** 5583122	Dec 10, 2013	DS DP U-756		**>A>** I-309	Aug 11, 2009
	>A> 5583122	Dec 10, 2013	DS DP U-222		**>A>** PED	Feb 11, 2010
	>A> 5583122*PED	Jun 10, 2014				
	>A> 5994329	Jul 17, 2018	U-353			
	>A> 5994329*PED	Jan 17, 2019				
	>A> 6015801	Jul 17, 2018	U-353			
	>A> 6015801*PED	Jan 17, 2019				
	>A> 6096342	Nov 22, 2011	DP			
	>A> 6096342*PED	May 22, 2012				
	>A> 6165513	Jun 10, 2018	DP			
	>A> 6165513*PED	Dec 10, 2018				
	>A> 6432932	Jul 17, 2018	U-595			
	>A> 6432932*PED	Jan 17, 2019				
	>A> 6465443	Aug 14, 2018	DP			
	>A> 6465443*PED	Feb 14, 2019				
RISEDRONATE SODIUM - ACTONEL						
020835 004	**>A>** 5583122	Dec 10, 2013	DS DP U-353		**>A>** D-105	Apr 16, 2010
	>A> 5583122*PED	Jun 10, 2014			**>A>** PED	Oct 16, 2010
	>A> 6096342	Nov 22, 2011	DP U-353			
	>A> 6096342*PED	May 22, 2012				
	>A> 6165513	Jun 10, 2018	DP			
	>A> 6165513*PED	Dec 10, 2018				
RISEDRONATE SODIUM - ACTONEL						
020835 005	**>A>** 5583122	Dec 10, 2013	DS DP U-353		**>A>** NS	Apr 22, 2011
	>A> 5583122*PED	Jun 10, 2014			**>A>** PED	Oct 22, 2011
	>A> 6165513	Jun 10, 2018	DP			
	>A> 6165513*PED	Dec 10, 2018				
	>A> 7192938	May 06, 2023	U-353			
	>A> 7192938*PED	Nov 06, 2023				
RISPERIDONE - RISPERIDONE						
076440 001					PC	Jul 29, 2009
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
022008 006	**>A>** 5422123	Jun 06, 2012	DP		**>A>** NDF	Jun 13, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SALMETEROL XINAFOATE - SEREVENT						
020692 001	5590645	Mar 01, 2011	DP			
	5590645*PED	Sep 01, 2011				
	5860419	Mar 01, 2011	DP			
	5860419*PED	Sep 01, 2011				
	5873360	Feb 23, 2016	DP			
	5873360*PED	Aug 23, 2016				
	6032666	Mar 01, 2011	DP			
	6032666*PED	Sep 01, 2011				
	6378519	Mar 01, 2011	DP			
	6378519*PED	Sep 01, 2011				
	6536427	Mar 01, 2011	DP			
	6536427*PED	Sep 01, 2011				
	6792945	Mar 01, 2011	DP			
	6792945*PED	Sep 01, 2011				
	7225808	Mar 01, 2011	DP			
	7225808*PED	Sep 01, 2011				
	7389775	Mar 01, 2011	DP			
	7389775*PED	Sep 01, 2011				
SILODOSIN - RAPAFLO						
022206 001	5780485	Nov 13, 2012	U-902			
SILODOSIN - RAPAFLO						
022206 002	5780485	Nov 13, 2012	U-902			
SINECATECHINS - VEREGEN						
021902 001	5795911	Oct 31, 2020	U-172			
SOMATROPIN RECOMBINANT - HUMATROPE						
019640 001					I-585	Mar 12, 2012
SOMATROPIN RECOMBINANT - HUMATROPE						
019640 004	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
SOMATROPIN RECOMBINANT - HUMATROPE						
019640 005	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
SOMATROPIN RECOMBINANT - HUMATROPE						
019640 006	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
SOMATROPIN RECOMBINANT - HUMATROPE						
019640 007	5612315	Mar 18, 2014	DP		I-585	Mar 12, 2012
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
021148 004	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
021148 005	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
021148 006	5849700	Dec 15, 2015	U-340			
	5849704	Dec 15, 2015	DP U-340			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX						
021148 007	5849700	Dec 15, 2015	U-340		I-572	Oct 31, 2011
	5849704	Dec 15, 2015	DP U-340		I-551	Sep 20, 2010
					I-536	May 31, 2010
					ODE	May 31, 2014
SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE						
076572 001					**>A>** PC	Aug 08, 2009
SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE						
076840 001					**>A>** PC	Aug 08, 2009
SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE						
076840 002					**>A>** PC	Aug 08, 2009
SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE						
076840 003					**>A>** PC	Aug 08, 2009
SUNITINIB MALATE - SUTENT						
021938 004	6573293	Feb 15, 2021	DS DP U-703		NCE	Jan 26, 2011
	7125905	Feb 15, 2021	DS DP			
	7211600	Dec 22, 2020	U-883			
TELBIVUDINE - TYZEKA						
022154 001					**>A>** NCE	Oct 25, 2011
TEMOZOLOMIDE - TEMODAR						
022277 001	5260291	Aug 11, 2013	DS DP U-619			
	5260291*PED	Feb 11, 2014				
	6987108	Sep 08, 2023	DP			
TIGECYCLINE - TYGACIL						
021821 001					I-588	Mar 20, 2012
					I-587	Mar 20, 2012
					I-586	Mar 20, 2012
TOPIRAMATE - TOPAMAX						
020505 001	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020505 002	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020505 003	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020505 004	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020505 005	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020505 006	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2009

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TOPIRAMATE - TOPAMAX						
020844 001	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX						
020844 002	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPAMAX SPRINKLE						
020844 003	7498311	Oct 13, 2015	U-955			
	7498311*PED	Apr 13, 2016				
TOPIRAMATE - TOPIRAMATE						
076448 001					**>A>** PC	Oct 12, 2009
TOPIRAMATE - TOPIRAMATE						
076448 002					**>A>** PC	Oct 12, 2009
TOPIRAMATE - TOPIRAMATE						
077868 001					**>A>** PC	Oct 12, 2009
TOPIRAMATE - TOPIRAMATE						
077868 002					**>A>** PC	Oct 12, 2009
TRAMADOL HYDROCHLORIDE - RYZOLT						
021745 001					NP	Dec 30, 2011
TRAMADOL HYDROCHLORIDE - RYZOLT						
021745 002					NP	Dec 30, 2011
TRAMADOL HYDROCHLORIDE - RYZOLT						
021745 003					NP	Dec 30, 2011
TRYPAN BLUE - MEMBRANEBLUE						
022278 001					NCE	Dec 16, 2009
					ODE	Dec 16, 2011
ZOLEDRONIC ACID - RECLAST						
021817 001					I-584	Mar 15, 2012
					I-581	Dec 19, 2011
ZOLPIDEM TARTRATE - EDLUAR						
021997 001	6761910	Sep 24, 2018	DP U-674			
ZOLPIDEM TARTRATE - EDLUAR						
021997 002	6761910	Sep 24, 2018	DP U-674			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 29th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm